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ABSTRACT  
Human immunodeficiency virus (HIV) infection is effectively controlled with 
combination antiretroviral therapy (cART). However, cART is insufficient to either 
purge HIV from the body or fully correct immunological imbalances acquired 
during acute infection. The gut contains the largest proportion of immunological 
cells in the body and is a primary target for initial and ongoing HIV replication in 
patients. cART patients exhibit alterations to memory T cell populations and 
develop gastrointestinal (GI) damage during infection. These are linked with 
microbial translocation, which is thought to be a primary source of inflammation 
in patients. Understanding the key cellular contributors to intestinal damage 
might provide insights into improving patient therapeutics and quality of life.  
In this dissertation we examined whether or not a rapidly progressing 
SIV/pigtailed macaque model of HIV disease exhibits enteropathy, microbial 
translocation, and alterations to memory T cells populations similar to those seen 
in HIV-infected patients. Quantitative histological evaluation revealed that half of 
late stage infected (LSI) animals exhibited intestinal disease. 
Immunohistochemical staining combined with in situ hybridization revealed that 
intestinal disease was highly associated with T cell loss, increased cell death, 
increased numbers of SIV-infected cells, and decreased epithelial integrity. T cell 
numbers, epithelial integrity, and numbers of cytotoxic T lymphocytes were 
preserved in LSI animals without intestinal disease. Unexpectedly, measurement 
of plasma protein and DNA markers of microbial translocation revealed minimal 
evidence of microbial translocation. 
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Flow cytometry analysis showed a reduction in number of CD4+ T cells in 
the blood and gut of LSI animals. cART initiated during acute infection restored 
CD4+ T cells in the blood and colon and prevented intestinal disease. cART plus 
the CCR5 antagonist Maraviroc (cART+M) improved restoration of CD4+ and 
CD8+ memory T cell populations over cART alone. cART+M also markedly 
increased CD27 expression on memory T cells in all body regions indicating 
earlier differentiation of cells. Finally, markers of T cell activation were reduced in 
animals treated with cART+M. These findings provide unique insights into the 
status of the gut both physiologically and immunologically during HIV/SIV 
infection. Further, our findings with cART in combination with Maraviroc suggest 
a beneficial therapeutic opportunity for patients. 
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HIV, Inflammation, and Microbial Translocation 
 The modern era of human immunodeficiency virus (HIV) is defined by the 
achievement of combination antiretroviral therapy (cART) in suppressing viral 
replication in infected patients. This suppression has led to individuals living 
longer, healthier lives (1). Despite the success of cART, it is insufficient to either 
purge the latent reservoir of virus-infected cells or fully correct the immunological 
imbalances acquired during acute HIV infection (2, 3). In the plasma of patients 
on cART there is ongoing evidence of low-level viral replication (4, 5). In 
chronically infected individuals, there is ongoing indication of systemic 
inflammation in the plasma along with an increased risk for non AIDS-related 
events such as cardiovascular, hepatic, and renal diseases (6). Risk factors for 
these non-AIDS events include elevated C-reactive protein (CRP), D-Dimer, IL-6, 
and hyaluronic acid (7). These inflammatory markers do not resolve even with 
suppression of viral replication by cART (8). One of the main triggers for this 
systemic inflammation is thought to be increased microbial translocation due to 
an impaired mucosal immune system and resulting intestinal damage, which 
does not resolve with cART (9). This translocation along with the amount of 
CD4+ T cell recovery after cART implementation predict HIV disease progression 
and the overall prognosis of patients (10-12).  
Natural controllers of HIV replication have much more complete 
restoration of CD4+ T cell populations in the blood, which coincides with control 
of viral replication. However, these individuals do not experience a reduction in 
some indicators of systemic inflammation, which coincide with non AIDS events 
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such as cardiac disease (13). Additionally, in some cohorts of controllers, 
indicators of microbial translocation such as lipopolysaccharide are elevated 
compared to uninfected individuals and are associated with loss of viral control 
(14). These observations that persist even in the presence of natural viral 
suppression and effective cART drivers of systemic inflammation have driven 
researchers to define the immunological parameters that frame these events. 
Better understanding of these immunological players should shed light on 
changes independent of viral replication that contribute to persistent 
inflammation. 
 
HIV-Associated Intestinal Dysfunction and Immunological Impairment 
 Since the beginning of the AIDS epidemic, gastrointestinal (GI) 
complications have been noted by clinicians. Over half of all HIV-infected 
patients suffer from symptoms such as pain and diarrhea. Additionally, nearly all 
patients on long term cART therapy exhibit GI complications at some point (15). 
These GI manifestations are multifaceted and might include gastritis, enteritis, 
and upper and/or lower GI opportunistic infections with viral, microbial, and 
protozoal organisms (16). Evaluation of clinical hematoxylin and eosin (H&E)-
stained intestinal sections by a pathologist is sufficient to make a diagnosis of 
HIV-associated GI disease. More detailed differential diagnoses might be made 
that implicate specific pathogens contributing to overall disease using a variety of 
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techniques such as polymerase chain reaction (PCR), immunohistochemistry 
(IHC), and in situ hybridization (ISH) (17). 
 Enteropathy observed in HIV-infected individuals, with and without cART, 
is a consequence of complex and devastating immunological imbalances 
triggered by HIV replication. Since the late 1980s it has been noted that CD4+ T 
cells are rapidly and dramatically lost in the GI tract, specifically the jejunum, of 
acutely and chronically HIV-infected individuals (18, 19). These T cell populations 
do not recover upon implementation of cART (20-22). In models of HIV disease 
similar findings have been observed with regards to GI disease, depletion of 
CD4+ T cells, and subsequent inadequate recovery after initiation of cART (23-
28). These reductions in the number of CD4+ T cells in the intestinal mucosa 
specifically involve alterations in the numbers of and activation state of 
specialized lineages of T cells including central and effector memory cells, 
intermediately differentiated memory cells, Th17 cells, and T regulatory cells in 
both humans and SIV infected primates. Alterations to the balance of these 
specialized T cells result in reduced production of the proliferative cytokine 
interleukin 2 (IL-2) and increased production of pro-inflammatory cytokines such 
as macrophage inflammatory protein 1 (MIP-1) and interferon gamma (IFN). 
Overall, these changes contribute to a maladaptive mucosal immune system that 
leads to increased local inflammation (29-37). 
Macrophages are a large constituent of the gut and are typically of an anti-
inflammatory phenotype. Macrophages of the gut normally function to eliminate 
cellular debris from the local microenvironment. They’re largely localized to the 
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basolateral surface of the epithelium and are constantly receiving anti-
inflammatory signals from the surrounding lamina propria (38-40). During acute 
and chronic HIV infection they are infected, yet reportedly they persist and even 
accumulate concurrently with the loss of CD4+ T cells (38). During chronic HIV 
infection and in patients receiving cART, their phenotype shifts to a pro-
inflammatory state. This results in increased expression of pro-inflammatory 
cytokines such as tumor necrosis factor alpha (TNF), IFN, and interleukin 1b 
(IL1) (39-43). This shift in macrophage and T cell cytokine expression along 
with the loss of specialized T cell populations are the foundation of 
immunological dysfunction during HIV/SIV infection of the gut mucosa; leading to 
disruption of normal GI function and the ability of the tissue to respond to 
pathogens, clear cellular debris, and control inflammation.  
 
The Challenges of Studying Microbial Translocation 
 HIV and SIV associated immunological impairment of the mucosal 
immune system is generally associated with breakdown of the mucosal barrier 
ultimately resulting in increased microbial translocation both during acute and 
chronic HIV infection, and with cART (12, 36, 41-45). There are several 
indicators of microbial translocation used to measure the amount of translocation 
occurring. These include but are not limited to: lipopolysaccharide (LPS), soluble 
CD14 (sCD14), LPS binding protein (LBP), and 16s ribosomal DNA (16s rDNA). 
These various assays have been used to predict both disease outcome as well 
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as the amount of immunological restoration HIV-infected patients on cART 
undergo with varying degrees of success (46-49). Further, some groups have 
reported methodological limitations of several of these assays; highlighting the 
need for thorough and rigorous evaluation of translocation using several 
approaches (46, 50, 51). 
 
Project Overview 
 As previously discussed, there is strong evidence that HIV/SIV-associated 
disruption of the gut mucosal immune system is central to the ongoing 
inflammation experienced by chronically HIV-infected patients and those on 
cART. Given the complex physiology and immunology of the GI tract, 
approaches that attempt to evaluate the severity of HIV/SIV associated 
enteropathy, define its immunological basis, and potentially associate findings 
with increased microbial translocation and inflammation need to be rigorous and 
thorough. While there is evidence of microbial translocation and a body of 
research indicating its importance in driving HIV/SIV disease, rarely do studies 
seek to evaluate intestinal pathology alongside immunological changes and 
microbial translocation. Approaches that include detailed examination of specific 
aspects of disease in combination with those that seek to broadly evaluate many 
aspects of disease in a single system might help to clarify some confusion 
regarding the topic. Additionally, these findings might reveal potential 
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opportunities for improved therapeutics by highlighting the most potent drivers of 
inflammation in the gut and systemically. 
 While enteropathy has been described in HIV-infected humans and some 
SIV models of HIV infection, it has not been examined in the accelerated 
SIV/macaque dual inoculation model of HIV. This model exhibits a course of 
disease similar to SIV-infected rhesus macaques but in a compressed time span 
resulting in death around three months post inoculation, and infected animals can 
achieve viral suppression on cART therapy (52). This model has previously 
provided unique insights into various aspects of the disease that develop 
longitudinally in the host, such as HIV-associated neurocognitive disease 
(HAND). Further, this model has served as a system to test novel neurological 
and systemic therapeutics (53-56).  
The aim of this dissertation was to examine whether or not this rapidly 
progressing SIV/pigtailed macaque model of HIV disease exhibits enteropathy, 
microbial translocation, and alterations to memory T cells populations similar to 
those seen in HIV-infected patients. In Chapter II we show that intestinal disease 
develops in half of infected macaques during late stage infection (LSI), and is 
prevented by cART initiated during acute infection. This intestinal disease was 
most severe in the ileum and colon, and as such we chose these two regions for 
further analysis. In the ileum and colon, intestinal disease was associated with 
increased cellular apoptosis via caspase-3 staining, decreased staining for CD3+ 
T cells via immunohistochemistry (IHC), and an increased number of SIV-
infected cells via in situ hybridization (ISH). In LSI animals that did not develop 
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intestinal disease, CD3+ T cells were preserved. Further, for all LSI animals, 
levels of CD3 staining in the gut mucosa strongly correlated with the number of 
infected cells in the gut mucosa, plasma viral load, and caspase-3 staining. 
Surprisingly, there was little evidence of microbial translocation in the plasma as 
measured by soluble CD14, soluble CD163, lipopolysaccharide binding protein; 
or in the plasma, mesenteric lymph nodes, and liver as measured by microbial 
16s ribosomal DNA. To explore this finding further, we examined ileum and colon 
samples from animals during acute and asymptomatic infection for loss of 
epithelial integrity indicated by loss of staining for the tight junction protein 
claudin-3. Claudin-3 loss was not observed during acute infection despite 
significantly less staining for CD3+ T cells. However, claudin-3 was reduced in 
LSI animals with severe intestinal disease although this did not predict increased 
microbial translocation. LSI animals that did not develop intestinal disease had 
increased TIA-1-positive cytotoxic T lymphocytes (CTLs) suggesting a robust, 
adaptive, CTL response might, in part, confer resilience to SIV induced intestinal 
damage. Thus, in this accelerated SIV macaque model, microbial translocation 
occurs during late stage infection and might be associated with an alternative 
pathway to microbial antigen induction independent of intestinal disease and 
epithelial damage. 
In Chapter III of this dissertation we conduct a detailed analysis of naive, 
central, and effector memory T cells, and their expression of CD27, CCR5, 
CCR7, and HLA-DR in the blood, gut mucosa (jejunum, ileum, and colon), and 
draining gut and peripheral lymph nodes of uninfected animals in comparison 
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with those during late stage infection (LSI); and animals receiving cART, and 
cART plus Maraviroc (cART+M) using multicolor flow cytometry. The numbers of 
CD4+ T cells were lower in the blood and in all areas of the gut mucosa of LSI 
animals. These reductions were restored with cART in the blood, ileum, and 
colon; and with cART+M in the blood and colon. cART+M improved restoration of 
CD4+ and CD8+ naive and central memory T cells towards proportions seen in 
uninfected animals as compared to cART alone in the gut mucosa. cART+M also 
markedly increased CD27 expression on naïve, central, and effector CD4+ 
memory T cells in all body regions, and on central, and effector CD8+ memory T 
cells in the ileum and colon. Increased CD27 expression indicates the cells are 
less terminally differentiated and as such are more able to respond effectively 
and appropriately to inflammatory stimuli. Finally, reductions were observed in 
CCR7 in the blood and HLA-DR in the gut mucosa on CD4+ and CD8+ memory 
T cells indicating a reduction in activation of T cells. Overall, these findings 
indicate that while cART might be effective at preventing the development of 
intestinal disease as evaluated by histopathology, therapeutic regimens can be 
further improved to yield additional restoration of the mucosal immune system. 
Additionally, we identify a drug already in use for HIV therapy, the CCR5 receptor 
antagonist Maraviroc, that is capable of restoring the proportions of memory T 
cells in infected animals towards those seen in uninfected animals while reducing 
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 Enteropathy in human immunodeficiency virus (HIV) infection is not 
eliminated with combination antiretroviral therapy (cART), and is possibly linked 
to microbial translocation. We used a rapidly progressing SIV/pigtailed macaque 
model of HIV to examine enteropathy and microbial translocation. Histological 
evidence of intestinal disease was observed in only half of infected macaques 
during late stage infection (LSI). cART initiated during acute infection prevented 
intestinal disease. In the ileum and colon, enteropathy was associated with 
increased caspase-3 staining, decreased CD3+ T cells, and increased SIV-
infected cells. CD3+ T cells were preserved in LSI animals without intestinal 
disease and levels of CD3 staining in all LSI animals strongly correlated with the 
number of infected cells in the intestine and plasma viral load. Unexpectedly, 
there was little evidence of microbial translocation as measured by soluble CD14, 
soluble CD163, lipopolysaccharide binding protein, and microbial 16s ribosomal 
DNA. Loss of epithelial integrity indicated by loss of the tight junction protein 
claudin-3 was not observed during acute infection despite significantly fewer T 
cells. Claudin-3 was reduced in LSI animals with severe intestinal disease but did 
not correlate with increased microbial translocation. LSI animals that did not 
develop intestinal disease had increased TIA-1 positive cytotoxic T lymphocytes 
(CTLs) suggesting a robust adaptive CTL response might, in part, confer 




 With the implementation of combination antiretroviral therapy (cART) 
human immunodeficiency virus (HIV)-infected people are living longer, healthier 
lives. The number and median age of people living with HIV has increased 
rapidly since the pre cART era with over 37 million individuals infected worldwide 
(1). As this population grows and ages, management of chronic HIV-associated 
conditions is becoming of increasing importance in the health community. 
  Over half of all HIV-infected patients suffer from gastrointestinal (GI) 
symptoms such as pain and diarrhea. Additionally, nearly all patients on long 
term cART therapy exhibit GI complications at some point (2). These 
complications have been evident since the beginning of the AIDS epidemic and 
are often multifaceted including gastritis, enteropathy, and upper and/or lower GI 
opportunistic infection with viral, microbial, and protozoal organisms (3). Visual 
evaluation of hematoxylin and eosin (H&E) stained intestinal sections is sufficient 
to make a diagnosis of HIV-associated GI disease. Additionally, differential 
diagnoses might be made implicating specific pathogens contributing to overall 
disease using a variety of techniques such as polymerase chain reaction (PCR), 
immunohistochemistry (IHC), and in situ hybridization (ISH) (4). 
 The pathological changes that occur in the gut of HIV-infected individuals, 
both cART treated and untreated, are thought to result from complex HIV-
induced immunological changes. CD4+ T cells are rapidly and dramatically 
decreased in the GI tract of acutely and chronically HIV-infected individuals and 
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are often reported to recover incompletely with implementation of cART (5, 6). 
Some specialized lineages of T cells including Th17 cells and T regulatory cells 
are affected by this loss contributing to the inflammatory imbalance (7). 
Macrophages, which are a large constituent of the gut and typically of an anti-
inflammatory profile, are infected early on. However, they persist and even 
accumulate concurrently with the loss of CD4+ T cells (8, 9). Dendritic cells, 
which assume an antigen-presenting role in the gut, are rapidly lost with 
infection, and are replaced by pro-inflammatory pDCs even in patients on cART 
(10). These overall shifts in immunological cell populations disrupt normal GI 
function as well as the ability of the tissue to respond to pathogens, clear cellular 
debris, and control inflammation.  
As studying the nature of HIV-associated GI disease in patients is 
experimentally challenging, non-human primate (NHP) models of HIV using 
simian immunodeficiency virus (SIV) provide a unique window of insight into the 
course of this disease. Exhibiting a similar course of disease both virologically 
and immunologically, many of these models have been reported to have 
pathological changes in the gut and significant alterations in the gut-associated 
lymphoid tissue (GALT) that are similar to humans with HIV (11, 12). 
In both HIV-infected humans and SIV-infected NHPs the intestinal disease 
caused by immunological dysfunction is thought to result in disruption of the gut 
barrier. This disruption might be sufficient to allow translocation of microbial 
products and microbes themselves into the lymphatic system and blood stream. 
This translocation, which is thought to be a main source of systemic inflammation 
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and ultimately an important component of terminal opportunistic infection, is not 
wholly restored with cART treatment in either humans or NHPs (13-15). 
Additionally, recent advances in the study of the microbiota in human 
health and disease have expanded our understanding of the role of the gut 
during disease progression. Shifts in the microbiome been associated with 
disease outcome in humans and have provided insights into potential 
mechanisms associated with cART therapy and even protection conferred from 
experimental vaccine approaches (16, 17). 
While enteropathy has been identified and evaluated in HIV-infected 
humans and some NHP models of HIV infection, it has not been examined in the 
accelerated SIV/macaque dual inoculation model of HIV (18). Briefly, this model 
exhibits a course of disease similar to SIV-infected rhesus macaques but in a 
compressed time span resulting in death around three months post inoculation, 
and infected animals can achieve viral suppression on cART therapy. This model 
has previously provided unique insights into various aspects of the disease that 
develop longitudinally in the host, including HIV-associated neurocognitive 
disease (HAND) (19). The aim of the present study was to evaluate the presence 
and severity of intestinal disease and its association with viral infection and/or 
alterations to cell populations in the GI tract of SIV dual virus-inoculated 
macaques. Specifically, changes to peripheral and GI viral burden, blood CD4+ T 
cell count, GI apoptosis, GI T cells and macrophages, intestinal tight junction 
continuity, indicators of microbial translocation, and translocation associated 
inflammation were evaluated. 
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Materials and Methods 
Animal studies 
Tissues from multiple cohorts of juvenile pigtailed macaques were studied 
retrospectively. All infected groups were inoculated intravenously with two strains 
of SIV, the immunosuppressive swarm SIV/DeltaB670 and the neurovirulent 
clone SIV/17E-Fr, as previously described (17). Infected, untreated animals were 
euthanized during various stages of disease (7, 10, 14, 21, 35, 42, 56, and 
approximately 84 days p.i.). Animals that were euthanized at 84 days or prior to 
that time if criteria for euthanasia were reached are herein referred to as late 
stage infection (LSI).  
Animals referred to as “cART” received a regimen including the nucleotide 
reverse-transcriptase inhibitor tenofovir (Gilead, Foster City, CA) at a dose of 30 
mg/kg subcutaneously once a day from days 12 to 26 p.i. and 10 mg/kg 
subcutaneously once a day thereafter; the protease inhibitors saquinavir (Roche, 
Basel, Switzerland) and atazanavir (Bristol-Myers Squibb, New York City, NY) at 
doses of 205 and 270 mg/kg orally twice a day, respectively; and the integrase 
inhibitor L-870812 (Merck, Kenilworth, NJ) at a dose of 10 mg/kg orally twice a 
day beginning at 12 days after virus inoculation. cART animals were monitored 
for virus in plasma and CSF by quantitative real-time PCR (qRT-PCR) and 
experienced marked declines in plasma and CSF viral RNA levels, reaching 
<100 copy equivalents/mL by ∼50 days after treatment initiation. cART animals 
were euthanized between 161-175 days post infection and have been described 
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in further detail previously (20). Animals referred to as procedural control (PC) 
were mock-infected and had blood sampled on the same experimental schedule 
as untreated late stage SIV-infected (LSI) animals. PC animals were euthanized 
at 84 days p.i. Animal groups evaluated in this study are summarized in Table 1-
1. 
  All animals were euthanized in accordance with federal guidelines and 
institutional policies. At euthanasia animals were anesthetized with ketamine-HCl 
followed by induction of deep anesthesia with pentobarbital and perfused with 
sterile PBS. Tissues were collected and either flash frozen or fixed with Streck 
tissue fixative (Streck, La Vista, NE) for subsequent use. All animal studies were 
approved by the Johns Hopkins Animal Care and Use Committee; all animals 
were humanely treated in accordance with federal guidelines and institutional 
policies. 
 
Histological scoring for intestinal disease 
 Following necropsy, tissues were fixed using Streck tissue fixative for one 
week at room temperature and then embedded in paraffin. Sections of the 
stomach, duodenum, jejunum, ileum, cecum, and colon were prepared and 
stained with hematoxylin and eosin. A semiquantitative scoring template was 
established in consultation with a board certified veterinary pathologist to 
evaluate several visual indicators of intestinal disease. The presence of mixed 
mononuclear cellular infiltrates, multinucleated giant cells, and parasites, were 
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qualitatively assigned a score of 0 (none), 1 (mild), 2 (moderate), or 3 (severe). 
Thickness and integrity of the epithelium was examined and assigned a score of 
0 (intact), 2 (possibly compromised), or 4 (markedly compromised). Villus and 
glandular fusion, loss, abscesses, dilation, lymphoid follicles, and submucosal 
mononuclear cells were individually assigned a score of 0 (absent), or 1 
(present). The sum of these scores was used as a measure of severity of 
intestinal disease in each section. The sum of all of the scores for each section 
was used to assign a severity score for each animal.  
To quantitate severity of intestinal disease, sections were blinded and 
systematically examined under light microscopy by a single investigator. A 
separate pathologist evaluated and scored all sections from 24 animals to control 
for observer bias. Each scoring criterion was individually correlated with total 
scores to ensure one criterion was not influencing overall results. No PC or cART 
animal had an intestinal disease score above the median score (27) for LSI 
animals. As a result, this number was used to define animals with and without 
intestinal disease. Animals with scores between the 50th and 75th percentile (27-
32) were said to have mild intestinal disease, animals with scores above the 75th 
percentile (33+) were said to have severe intestinal disease. 
 
Immunohistochemistry and in situ hybridization 
Double labeling of tissues using immunohistochemistry (IHC) and in situ 
hybridization (ISH) was performed by hand on fixed, paraffin-embedded tissue 
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sections. Sections were deparaffinized by baking at 60°C, then rehydrated 
through a graded alcohol series. Slides were then pretreated with 25 µg/mL of 
proteinase K (Roche Applied Science, Indianapolis, IN). In situ hybridization for 
SIV was performed using an antisense SIVmac239 digoxigenin-UTP-labeled 
riboprobe at a concentration of 1.75 ng/µL overnight at 51°C. After washing, anti-
digoxigenin antibody was applied for 1 h at 37°C followed by the addition of color 
substrate solution to slides overnight at 4°C. Uninfected tissues were used as 
controls. After washing, slides were then blocked with 1x Power Block 
(BioGenex) for 10 min before proceeding to immunohistochemistry. 
Secondary labeling for macrophages was accomplished by using a 
monoclonal antibody against CD68 (KP1, Dako, Glostrup, Denmark) at a 
concentration of 74 μg/L for 60 min at RT. Secondary labeling for T cells was 
accomplished using a polyclonal antibody against CD3 (A0452, Dako) at a 
concentration of 60 μg/mL for 60 min at RT. After washing, biotinylated 
secondary antibody was added for 30 min following which slides were washed 
and visualized using the Vector red alkaline phosphatase substrate kit (Vector 
Laboratories, Burlingame, CA). After staining, slides were washed, dehydrated 
and cover-slipped.  
Apoptosis was measured on tissue in the absence of ISH using a rabbit 
polyclonal antibody against caspase-3 (9661, Cell Signaling, Danvers, MA) at a 
concentration of 0.252 μg/mL for 15 min at room temperature. All caspase-3 
staining was conducted on the Leica Bond Rx automated tissue staining system 
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using the Leica Bond Polymer Refine staining kit using a 20 minute sodium 
citrate pretreatment.  
Epithelial tight junction protein claudin-3 was measured on tissue in the 
absence of ISH using a rabbit polyclonal antibody against claudin-3 (RB-9251, 
ThermoFisher, Waltham, MA) at a concentration of 4 μg/mL for 15 min at room 
temperate. All claudin-3 staining was conducted on the Leica Bond Rx 
automated tissue staining system using the Leica Bond Polymer Refine staining 
kit using a 20 minute sodium citrate pretreatment.  
Cytotoxic T lymphocytes were measured in tissue in the absence of ISH 
using a mouse monoclonal antibody against TIA1 (T-cell intracytoplasmic 
antigen) antibody at a concentration of 10 μg/mL for 15 min at room temperature. 
All TIA-1 staining was conducted on the Leica Bond Rx automated tissue staining 
system using the Leica Bond Polymer Refine Red staining kit using a 30 minute 
sodium citrate pretreatment.  
All tissue sections were evaluated and quantified using a Nikon Eclipse 
microscope fitted with a color Nikon DS-Ri1 camera and NIS Elements 
Acquisition and Analysis software (Version 3.22.00, Nikon, Tokyo, Japan). Slides 
were blinded and 4 x 4 to 8 x 8 grids of adjacent microscope fields were imaged 
at 200x power resulting in a composite image containing at least 16 microscopic 
fields. Composite images were then white balanced and background corrected. 
Quantitation for CD3, CD8, and caspase-3 was accomplished by defining regions 
of interest (ROI) manually between the muscularis mucosae and the gut lumen 
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including the epithelium. Peyer’s patches and lymphoid follicles were excluded 
due to their variability in numbers and location in the ileum and colon. ROIs were 
limited to those where the crypts/glands were in the same plane as the 
histological section. Several regions of interest were defined resulting a total of 
approximately 2 mm2 of mucosa analyzed. ROIs were analyzed for 
immunohistochemically positive cells using the same object count settings for 
each marker between all blinded samples resulting in both a percentage of ROI 
area (% ROI) and number of positive cells. The same ROIs on each slide were 
then manually scored for SIV-ISH-positive cells yielding a number of positive 
cells per ROI and a ratio of singly ISH-positive cells to those double positive for 
ISH and IHC. 
Percent loss of claudin-3 staining was calculated in an approach similar to 
that detailed by Estes et al (14). Briefly, the luminal surface of the epithelium was 
traced and measured on composite images of the gut lamina propria resulting in 
a boundary at least 1mm in length. Then, all stretches of the epithelium lacking 
claudin-3 staining were traced and measured. The sum of the lengths of 
epithelium lacking claudin-3 staining were divided by the overall length of the 
epithelium and multiplied by 100 to yield a percent loss of claudin-3. 
The number of cells positive for TIA-1 was evaluated by counting the total 
number of TIA-1 positive cells in three microscope fields where the crypts/glands 
were in the same plane as the histological section at 400 x magnification. The 
mean of these three counts was then calculated resulting in an average TIA-1 
positive cells number per field. 
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RNA extraction and qRT-PCR of SIV in plasma 
 Viral RNA was isolated from 400 mL of plasma collected terminally using 
the QIAamp MiniElute Virus Spin kit (Qiagen, Hilden, Germany). Samples were 
eluted in 40 μL of Tris and ethylenediaminetetraacetic acid buffer and analyzed in 
triplicate by quantitative realtime PCR, as described elsewhere (19). The limit of 
detection for the assay was established as 10 copies/reaction (100 copy 
equivalents/mL). 
 
CD4+ T cell count 
 Terminal blood CD4+ T cell count was obtained by evaluating total 
number of lymphocytes per mL of blood via CBC. Then, using multicolor FACS 
analysis, an absolute percentage of lymphocytes positive for CD4 was 
determined. This percentage was then multiplied by the absolute number of 
lymphocytes per mL of blood to determine the number of CD4 cells per mL 
blood. This method has been described in detail elsewhere. (22) 
 
DNA extraction and 16s rDNA qPCR in plasma and tissues 
DNA was extracted from 200 μL previously thawed plasma using the 
QIAmp DNA Mini kit (51304, Qiagen). DNA from liver and MLN was extracted 
from approximately 50 mg of disrupted frozen tissue using the DNeasy kit 
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(69504, Qiagen). Real time PCR results were obtained using the Microbial DNA 
qPCR Pan Bacteria 1 assay (Qiagen) on a CFX96 thermocycler (Biorad, 
Hercules, CA). A 16s rDNA standard was established using DNA from 1 mL of an 
overnight E. coli K12 (ER2925, NEB) culture. DNA was extracted from the E. coli 
cell pellet using the QIAmp DNA Mini kit (51304, Qiagen). DNA purity and 
concentration was measured using a Nanodrop spectrophotometer (ND-1000, 
BioRad). After determining the DNA concentration the number of genome 
equivalents was calculated using the known E. coli K12 genome size. A 1:15 8-
fold dilution series was then used to establish a standard curve down to <1 
genome per reaction. Limit of detection was established at <30 E. coli K12 
genome equivalents per reaction. 
 
Plasma sCD14, s163, & LBP  
 sCD14 was measured via sandwich ELISA on 100 μL thawed plasma in 
1:200 dilution using the human sCD14 Quantikine ELISA kit (R&D Systems, 
Minneapolis, MN). sCD163 was measured via sandwich ELISA on 50 μL 
undiluted thawed monkey plasma using the human sCD163 Quantikine ELISA kit 
(R&D Systems). LPS binding protein (LBP) was measured in 100 μL undiluted 
thawed monkey plasma using the human LBP ELISA kit (Abnova, Taipei City, 




 Comparisons between two treatment groups were done using Mann-
Whitney tests. Comparisons between multiple treatment groups were done using 
Kruskal-Wallis tests followed by Dunn’s multiple comparisons tests between the 
mean ranks of every group. Correlations were determined using Spearman's 
rank correlation tests, or Pearson’s correlation tests. p values for multiple 
correlations were corrected using Benjamini Hochberg multiple comparisons 
correction. Microsoft excel 2013 was used to organize data and generate 
descriptive statistics. GraphPad Prism 6.0 was used to perform all other 
statistical analyses and generate graphs. Graphs showing Kruskal-Wallis group 




Intestinal disease scoring criteria 
 To evaluate the impact of each intestinal disease scoring criteria on the 
total score, the criteria were broken down into four main categories; giant cells, 
cellular infiltrates, epithelium integrity, and villus/gland disruption. The descriptive 
statistics for LSI and PC animals were compared and the average scores for 
each disease indicator category compared (Table 1-2). LSI animals scored 
higher in all categories than PC animals. Multinucleated giant cells were not 
observed in PC animals but were seen in 58.3% of LSI animals. Mixed cellular 
infiltrates were observed in all animals as some density of lymphocytes and 
macrophages are normal in the lamina propria of the gut. The epithelium was 
compromised in 29.1% more LSI animals than PC animals. Abnormal villi and 
glands were only observed in 8.3% of PC animals but were observed in 66.7% of 
LSI animals.  
Pearson’s correlation tests were carried out between each of the four 
categories (giant cells, cellular infiltrates, epithelium integrity, and villus/glad 
disruption) and the overall intestinal disease score for LSI animals. All four 
categories significantly correlated with the overall intestinal disease score. 
However, none of the correlations was especially strong. Of the categories, villus 
and glandular abnormalities were the best predictors of total intestinal disease 
severity (r = 0.50, r2 = 0.25, p < 0.0001). Cellular infiltrates were the worst 
predictors of total intestinal disease severity (r = 0.26, r2 = 0.07, p < 0.0001). 
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Detailed evaluation of the intestinal severity scoring criteria both total and by 
anatomical location are described in Supplemental tables 1-1, 1-2, and 1-3.  
 
Intestinal disease scores  
 The first goal was to unbiasedly characterize the nature of any observable 
histopathological changes in several cohorts of SIV-infected macaques. These 
groups included: uninfected procedural control animals (PC), infected animals 
euthanized at various stages of infection, and infected animals treated with 
combination antiretroviral therapy (cART) starting at day 12 post inoculation. 
Information on animal groups is summarized in Table 1-1. 
 Tissues from each animal were evaluated for indicators of intestinal 
disease using a scoring system detailed in the methods section. Briefly, changes 
such as mixed cellular infiltration, villus and glandular disruption, presence and 
overgrowth of microflora, and disruption of the epithelium were evaluated and 
individually assigned scores; the sum of which indicated that GI region’s severity 
of intestinal disease. The sum of the scores for all regions of the gastrointestinal 
tract represented each animal’s overall intestinal disease score. Representative 
images of normal animals, and animals with several of these disease indicators 
are depicted in Figure 1-1 A-F. 
 There was a significant difference in the mean rank between all of the 
animal groups examined (Figure 1-1G; H = 22.73, p < 0.0001). Specifically, late 
state infected (LSI) animals exhibited significantly more intestinal disease than 
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matched procedural control (PC) animals (p = 0.0002) (Figure 1-1H). 
Interestingly, animals that received combination antiretroviral therapy (cART) had 
levels of intestinal disease that were significantly lower than LSI animals and 
were similar to PC animals (p = 0.0129) (Figure 1-1H). Of the other time points 
examined, only two animals euthanized at day 56 post-infection had scores 
above 27; both of these had mild enteropathy (Figure 1-1G). 
 
Relationship between intestinal disease, plasma viral load, and blood CD4+ T 
cell count 
 Severity of intestinal disease was compared with terminal plasma viral 
load (pVL) and terminal blood CD4+ T cell count for all LSI animals, both with 
and without enteropathy. There was no overall correlation with all LSI animals. 
However, when animals with mild or severe intestinal disease were examined 
separately, there was a highly significant positive correlation between plasma 
viral load and the severity of intestinal disease (r = 0.841, p = 0.0006) (Figure 1-
1I). Additionally, in animals with severe intestinal disease there was a significant 
negative correlation between terminal blood CD4 count and severity of intestinal 
disease (r = -0.9710, p = 0.011) (Figure 1-1J).  
 
Intestinal disease by intestinal region 
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 With the exception of the duodenum, all intestinal sites examined trended 
towards or had significantly different mean ranks of intestinal disease between 
PC, cART, and LSI animals (Figure 1-2A-F). The strongest statistical differences 
in mean rank of intestinal disease were found in the ileum (H = 16.51, p = 
0.0003) and colon (H = 23.00, p < 0.0001) (Figure 1-2D, F). All group differences 
represented a significant increase or trend towards an increase in the mean rank 
of intestinal disease in LSI animals. The most significant elevations in mean rank 
of intestinal disease between PC and LSI animals were in the ileum (p = 0.0025) 
and colon (p < 0.0001). With these findings, we selected the ileum and colon for 
subsequent study.  
 
Caspase-3 expression in ileum and colon 
Caspase-3 expression was measured using immunohistochemistry (IHC) 
to evaluate the levels and locations of apoptosis in the ileum and colon of PC 
animals compared with LSI animals with or without severe intestinal disease 
(LSI-Severe or LSI-None). In PC animals, caspase-3 was concentrated in 
proximity to the gut lumen; the tips of the villi in the ileum and the superficial 
lamina propria of the colon (Figure 1-3A, B). However, in LSI-Severe animals, 
caspase-3 localized around areas of villus loss in the ileum and glandular 
degeneration in the colon (Figure 1-3C, D). There was a significant difference in 
the mean rank of percent region of interest (% ROI) positive for caspase-3 
between PC, LSI-None, and LSI-Severe animals in the ileum (H = 8.769, p = 
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0.0012) and colon (H = 5.692, p = 0.0487) (Figure 1-4A, B). The % ROI positive 
for caspase-3 was found to be significantly increased in LSI-Severe animals as 
compared with PC animals in the ileum (p = 0.0098) and trended towards an 
increase between LSI-None and LSI-Severe animals in the colon (p = 0.0930).  
 
CD3 expression and distribution in the ileum and colon 
 Slides from the ileum and colon of PC animals, LSI-None, and LSI-Severe 
animals were dually labeled for CD3 and SIV using IHC and in situ hybridization 
(ISH). In PC animals, CD3 positive cells were distributed evenly throughout the 
lamina propria in the ileum and colon (Figure 1-3E, F). However, in LSI-Severe 
animals, what CD3 positive cells remained congregated in foci located around 
the muscularis mucosae (Figure 1-3G, H). There was a significant difference in 
the mean rank of the % ROI positive for CD3 between PC, LSI-None, and LSI-
Severe animals in the ileum (H = 7.269, p = 0.0152) and colon (H = 7.538, p = 
0.0107) (Figure 1-4C, D). These group differences represented a significant 
decrease between the mean rank of the % ROI positive for CD3 between LSI-
None and LSI-Severe animals in the ileum (p = 0.0243) and colon (p = 0.0324). 
Additionally, while only approaching significance, CD3 % ROI tended to be 
significantly lower between PC and LSI-Severe animals in the colon (p = 0.0930).  
 
CD68 expression and distribution in ileum and colon 
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Slides from the ileum and colon of PC, LSI-None, and LSI-Severe animals 
were also dually labeled for CD68 and SIV using IHC and ISH respectively. In PC 
animals, CD68-positive cells were concentrated in proximity to the gut lumen: the 
tips of the villi in the ileum and near the basal surface of the colon epithelium 
(Figure 1-3I, J). However, in LSI-Severe animals, CD68-postive cells were evenly 
distributed throughout the lamina propria in the ileum and concentrated around 
degenerating glands in the colon (Figure 1-3K, L). In the colon there was a 
significant difference in mean rank of the % ROI positive for CD68 between PC, 
LSI-None, and LSI-Severe animals (H = 5.808, p = 0.0442) (Figure 1-4E, F). This 
represented a significant reduction in CD68 between PC animals and LSI-Severe 
animals (p = 0.0482). No differences in mean rank of the % ROI positive for 
CD68 in the ileum were found.  
 
SIV hybridization and double labeled cells in ileum and colon during late stage 
infection 
 Slides double-labeled for CD3/SIV or CD68/SIV were scored for number 
of cells that were positive for SIV RNA alone or double-labeled for SIV and 
CD68. Overall, the number of SIV-positive cells was significantly higher in the 
ileum but not in the colon of LSI-none as compared with LSI-Severe animals (p = 
0.0286) (Figure 1-5A). The total number of CD3/SIV or CD68/SIV double positive 
cells was not significantly different in the ileum or colon of LSI-None and LSI-
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Severe animals. However, CD68/SIV represented a larger proportion of double-
labeled cells than CD3/SIV in LSI-Severe animals (Figure 1-5B). 
 
Correlations between staining for caspase-3, CD3, and CD68 in ileum and colon 
and intestinal SIV or plasma viral load  
In all LSI animals the % ROI positive for CD3 but not CD68 was strongly 
correlated with SIV infection. After Bonferroni correction, the % ROI positive for 
CD3 was negatively correlated with the number of cells positive for SIV in the 
ileum (r = -0.8330, p = 0.0154) and showed a weak negative correlation in the 
colon (r = -0.6900, p = 0.1249) (Figure 1-6A, B). There also was a negative 
correlation in all LSI animals between the % ROI positive for CD3 and pVL, both 
in the ileum (r = -0.9430, p = 0.0177) and colon (r = -0.8860, p = 0.0428) (Figure 
1-6C, D). There were weak negative correlations between the % ROI positive for 
CD3 and the % ROI positive for caspase-3 in ileum (r = -0.619, p = 0.2300) and 
colon (r = -0.690, p = 0.1062) (Figure 1-6E, F).  
In the ileum, the % ROI positive for caspase-3 was positively correlated 
with pVL (r = 0.786, p = 0.0335). In the colon, the % ROI positive for caspase-3 
was positively correlated with the number of cells positive for SIV (r = 0.886, p = 
0.0461) (Figure 1-6G, H). Further, in all LSI animals regardless of intestinal 
disease severity, the number of cells positive for SIV RNA was positively 
correlated with pVL in the ileum (r = 0.9430, p = 0.0188) and trended positively in 
the colon (r = 0.8290 p = 0.0875) (Figure 1-6I). 
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Direct and indirect measures of microbial translocation in late stage infection 
Changes in soluble CD163 (sCD163), which measures increased 
macrophage activation that might be partially due to increased microbial 
translocation, were measured via ELISA. The mean rank of sCD163 was 
significantly different between PC, cART, and LSI animals (H = 13.09, p = 
0.0014). This difference indicated a strong trend towards elevation in sCD163 
mean rank in LSI animals with or without intestinal disease vs PC animals (p = 
0.0527) (Figure 1-7A).  
 Elevations in plasma soluble CD14 (sCD14) and LPS binding protein 
(LBP) are thought to result from translocation of microbes and their products, 
specifically LPS. Plasma sCD14 and LBP were evaluated using ELISA. The 
mean rank of sCD14 was significantly different between PC, cART, and LSI 
animals (H = 6.691, p = 0.0352). These differences indicated significant elevation 
of sCD14 in cART animals (p = 0.0388) and a trend towards elevation in LSI 
animals with or without intestinal disease (p = 0.0540) (Figure 1-7B). LBP mean 
rank trended similarly to sCD14 between PC, cART, and LSI animals (H = 4.940, 
p = 0.0846). This was due to a weak increase in LBP in LSI animals with or 
without intestinal disease (p = 0.1531) (Figure 1-7C) but no change in LBP levels 
in cART animals.  
 PCR for microbial 16s rDNA was conducted on plasma, liver, and 
mesenteric lymph node (MLN) tissue in order to directly detect microbial 
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translocation. In the plasma a significant difference was found between PC, 
cART, and LSI animals (H = 10.56, p = 0.0051). This was due to a significant 
increase in cART animals (p = 0.0024) but not LSI animals (Figure 1-7D). For 
both the liver and MLN, the median levels of 16s rDNA were not significantly 
different between PC, cART, and LSI animals (Figure 1-7E, F).  
No indicator of microbial translocation correlated with either pVL or 
terminal CD4 count via Spearman correlation. Further, no group differences were 
found when LSI animals were subdivided into those with (red squares) or without 
(black squares) severe intestinal disease. 
 Of note, for all of the assays except sCD14 several samples primarily in 
the PC and cART groups tested below the limits of detection for the given assay. 
As we are using a non-parametric approach to these analyses, which rely on 
rank-based comparisons, a meaningful statistical conclusion could not be drawn 
for several comparisons and the data should be therefore considered 
qualitatively. 
 
CD3 T cell and epithelial claudin-3 loss in the ileum and colon during acute and 
asymptomatic infection 
Ileum and colon of PC, acute (7 days p.i.), and asymptomatic (21 days 
p.i.) animals were labeled for CD3 and claudin-3 using IHC. There was a 
significant difference in the mean rank of the % ROI positive for CD3 between 
PC, acute, and asymptomatic animals in the ileum (H = 8.115, p = 0.0031) and 
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colon (H = 7.385, p = 0.0145) (Figure 1-8A, B). These group differences 
represented a significant decrease between the mean rank of the % ROI positive 
for CD3 between acute and asymptomatic animals in the ileum (p = 0.0134). 
While only approaching significance, CD3 % ROI trended towards being 
significantly lower between acute and asymptomatic or PC animals in the colon 
(p = 0.0558, p = 0.0558). There was no significant difference in the mean rank 
of % epithelium lacking claudin-3 staining between PC, acute, and asymptomatic 
animals (Figure 1-8C, D).  
 
Evaluation of epithelial claudin-3 loss and TIA-1 expression in the ileum and 
colon in late stage infection 
 Ileum and colon of PC, LSI-None, and LSI-Severe animals were labeled 
for claudin-3 and TIA-1 using IHC. There was a significant difference in the mean 
rank of % epithelium lacking claudin-3 staining between PC, LSI-None, and LSI-
Severe animals in the ileum (H = 5.808, p = 0.0442) and colon (H = 5.808, p = 
0.0442) (Figure 1-8E, F). These group differences represented a significant 
increase in the mean rank of % loss of claudin-3 between PC and LSI-Severe 
animals in the ileum (p = 0.0482) and colon (p = 0.0482). 
 There also was a significant difference in the mean rank of number of TIA-
1 positive cells per field between PC, LSI-None, and LSI-Severe animals in the 
ileum (H = 7.681, p = 0.0071) and colon (H = 8.578, p = 0.0017) (Figure 1-8G, 
H). These group differences represented a significant increase in the mean rank 
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of TIA-1 positive cells per field between PC and LSI-None animals in the ileum (p 




 The most remarkable findings of this study are that while discrete and 
severe intestinal disease develops in many late stage SIV-infected animals, 
those animals that do not develop intestinal disease have intact mucosal T cell 
populations similar to those in procedural control animals, despite significant 
declines in T cells in peripheral blood. Further, these T cell populations seem to 
be a key factor contributing not only to intestinal viral burden but to levels in the 
plasma as well. These phenomena appear to be independent of macrophage 
lineage cell populations in the gut despite a large proportion of virus-infected 
macrophages. Finally, and perhaps most unexpectedly, the presence or severity 
of enteropathy apparently had little to no impact on levels of microbial 
translocation in the animals with SIV infection status better predicting 
translocation.  
To our knowledge, this is one of few studies to comprehensively examine 
the entire gastrointestinal (GI) tract for the cellular and virological effects of SIV in 
pigtailed macaques. Further, it is the first to describe the effects of SIV on the GI 
tract in a rapidly progressing macaque model of HIV infection. Of the many 
microscopic criteria used to evaluate intestinal disease, abnormalities in villous or 
glandular structure were the most sensitive indicators of enteropathy. Human 
pathologists have cited similar criteria in HIV-infected patients as reliable 
indicators of intestinal disease (3, 4). Anatomically, the ileum and colon were the 
sites that exhibited the most severe pathological changes. This suggests that 
examination of villus and glandular structure in the ileum and colon are the most 
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efficient method for evaluating SIV-induced enteropathy in pigtailed macaques 
and likely other non-human primates. 
Some histopathological features in the gut of rapidly progressing SIV-
infected pigtailed macaques reflect previous observations in SIV/HIV-infected 
macaques and humans, while others appear unique to this model. In particular, 
histopathological evidence of enteropathy did not arise until 56 days post 
inoculation, when the macaques are undergoing the early stages of systemic 
immune depletion and recrudescence of plasma and tissue viral loads. 
Statistically significant pathological changes in the gut were not present until late 
stage disease, approximately three months post inoculation. This is in contrast to 
humans and the SIV/rhesus macaque model in which enteropathy appears early 
in infection and the histological lesions are sustained (3, 12, 24). 
We examined three groups of late stage SIV-infected animals: those with 
mild (LSI-Mild), severe (LSI-Severe), or no (LSI-None) intestinal disease. There 
was a highly significant positive correlation between intestinal disease severity 
scores and plasma viral load for all LSI animals with intestinal disease (LSI-Mild 
& LSI-Severe), and a strong negative correlation between terminal blood CD4+ T 
cell counts and severity of intestinal disease in LSI-Severe animals. This 
indicates that the GI tract is either sensitive to, or responsible for dramatic 
changes in systemic viral replication and associated systemic immunological 
dysfunction during chronic infection.  
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Intestinal disease in animals treated with combination antiretroviral 
therapy (cART) was absent, similar to procedural control (PC) animals 
suggesting that cART initiated during acute infection was effective at preventing 
the development of intestinal disease. This was also true in all gut sites 
examined. Numerous studies have examined the effectiveness of cART in 
restoring dysfunction of the gut in HIV-infected people. This has most thoroughly 
been evaluated by measuring restoration of CD4+ T cell populations in the gut 
with mixed results. Early intervention, similar to the cART regimen we used, often 
results in restoration of CD4+ T cells in various intestinal regions; later 
intervention is typically insufficient. (25) 
To better understand alterations to cellular processes and populations in 
the GI tract, we quantified cells undergoing apoptosis, the numbers of CD3+ T 
cells and CD68+ macrophages, and the relative numbers of SIV infected T cells 
and macrophages in PC, LSI-Severe and LSI-None animals. Increased caspase-
3 expression and TUNEL labeling as well as reduced tight junction proteins have 
been detected in chronically HIV-infected humans and SIV-infected macaques. 
These are associated with a dysfunctional gut barrier (12, 28, 29). In this study, 
LSI-Severe animals had a significant increase in caspase-3 
immunohistochemical staining in the ileum and trended towards an increase in 
the colon. These increases coincided with a shift in the location of positively 
stained cells from the superficial mucosa on villus tips and between colonic 
glands in PC and LSI-None animals, to discrete foci concentrated around 
degenerating villi and glands in LSI-Severe animals. These findings provide 
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experimental support for our histological observations that villus/glandular 
disruption might be the most predictive histological finding of intestinal disease. 
 It is widely known that the gut is a site of rapid HIV/SIV replication and 
loss of CD4+ T cells during acute infection, and that the GI tract does not 
typically recover from this damage (5, 6). In this study, there was no change to 
the organization of T cells in the gut between PC and LSI animals; CD3+ staining 
was evenly distributed throughout the lamina propria. However, in both the ileum 
and colon there was a significant and dramatic reduction in the amount of CD3 
staining in LSI-Severe animals. These findings agree with observations that T 
cell populations are ablated and do not recover after acute infection. However, 
concentrations of T cells in LSI-None animals were similar to those in uninfected 
animals demonstrating a previously unreported preservation of T cell populations 
in some chronically infected late stage animals.  
Some studies in untreated HIV-infected individuals have reported 
increased numbers of macrophages in the gut, perhaps due to their relative 
resistance to lytic HIV infection, and alterations in macrophage phenotype away 
from an inflammatorily anergic state towards a pro-inflammatory state in the gut 
(26-29, 8, 9). In this study, CD68+ cells in PC animals were found primarily in the 
peri-luminal portions of the villi in the ileum and glands in the colon. However, in 
LSI-Severe animals large numbers of CD68+ macrophages were detected 
surrounding foci of villus and glandular degeneration. In the colon there was a 
significant reduction in the level of CD68 immunostaining in LSI-Severe 
compared to PC animals. The decrease was found only in the colon, which 
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suggests that different environmental conditions exist in the colon and ileum that 
result in loss of macrophages in the colon only. These results are distinguished 
from the typical finding of preservation and even expansion of macrophage 
populations in the gut during SIV and HIV infection.  
The gut is a site of intense viral replication in acutely infected humans and 
macaques and of ongoing viral replication in the absence of cART. LSI-Severe 
animals had a significant increase in the number of virus-infected cells in the 
ileum and a trend towards an increase in the colon as compared to LSI-None 
animals. This increased viral replication was occurring despite tremendous 
depletion of T cells in both sites in LSI-Severe animals. There was an increase in 
the proportion of SIV-infected macrophages in LSI-Severe animals as compared 
to LSI-None. Again, this is despite reduction in the numbers of macrophages in 
the colon of LSI-Severe animals. These findings are unique as we saw low 
numbers of virus-infected cells in some LSI-None animals despite preservation of 
T cell populations and high viral loads in the plasma. 
There was a highly significant negative correlation between the number of 
SIV-positive cells and the level of CD3 staining, but not CD68 staining in the 
ileum of all LSI animals. A similar strong correlation trended towards significance 
in the colon. There also was a strong negative correlation between plasma viral 
load and level of CD3 staining, but not CD68 staining, in the ileum and colon. 
CD3 also showed a weak, negative correlation with caspase-3 staining. There 
was a strong positive correlation between caspase-3 staining and the number of 
SIV-infected cells in the ileum, and plasma viral load in the colon. Finally, the 
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number of cells positive for SIV in the ileum and colon positively correlated with 
the amount of virus in the plasma. It should be noted that despite having only 8 
samples per comparison these correlations were very strong.  
These data taken together with the histological observations indicate that 
intestinal disease in this model coincides with increased viral replication, both in 
the gut and blood, and the subsequent loss of T cells. Nonetheless, only about 
50% of animals with high viral loads and loss of peripheral blood T cells develop 
intestinal disease. Further, these data suggest that T cells and not macrophages 
are the primary contributors or regulators of virus production in the gut. This T 
cell-derived viral pool in the gut has a very strong relationship with the level of 
virus in the plasma regardless of the density of intestinal T cells and level of 
intestinal disease in the animal. This would indicate that in this model the gut is 
more reflective of the blood as a viral compartment and not the spleen or brain, 
which are primary influenced by macrophage infection and inflammation (30, 31).  
Indeed, GI tract macrophages arise from a lineage independent of many 
other tissue sites. They are primarily derived from blood monocytes and not the 
embryonically seeded progenitors that populate the spleen and brain (32). 
Perhaps late stage SIV infection in this model captures a physiological state 
close to death where loss of GI tract macrophages in the large intestine might be 
due to destruction of the seeding pool of blood monocytes and not reflective of 
direct infection of GI tract macrophages (33). 
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Unique to this study is the finding that gut T cell populations are preserved 
in late stage infection in the absence of enteropathy in a large proportion of 
animals. Plasma viral load and terminal CD4+ T cell counts only correlated with 
those LSI animals exhibiting intestinal disease whereas the level of CD3 staining 
in the gut correlated with plasma viral load for all LSI animals indicating that 
intestinal disease is secondary to the health of the gut T cell population. This 
agrees with the concept that lack of recovery of CD4 populations in the gut with 
cART therapy in humans predicts a poor clinical outcome.  
 Microbial translocation is a thought to be a common occurrence in 
chronically HIV-infected individuals and in those on cART, resulting from early 
destruction of the T cell populations in the gut and associated epithelial disruption 
(14-17). However, especially in people on cART, the relationship between T 
cells, intestinal damage, translocation, and inflammation is not clear. We 
examined several markers of microbial translocation in all groups of animals. 
Regardless of the assay used, there was no difference between LSI-None and 
LSI-Severe animals. All LSI animals had significantly increased plasma sCD163, 
a marker of macrophage activation, and plasma sCD14, a marker of macrophage 
and monocyte response to LPS as compared to procedural controls. In addition, 
plasma sCD14 was elevated in cART animals despite the absence of any 
intestinal damage. Plasma LBP was somewhat elevated in LSI animals, although 
this finding was not statistically significant.  
 We also examined levels of 16s rDNA in plasma, MLN, and liver. Plasma 
levels of 16s rDNA were increased in cART animals. The majority of LSI animals 
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had more plasma 16s rDNA than PC animals but not significantly so. There were 
no significant increases observed in the MLN or liver. The sensitivity of 16s rDNA 
qPCR might be inferior to that of other assays given the nature of endogenous 
DNAse activity by the host and 16s rDNA has been shown to be a poorer 
predictor of translocation and clinical outcome when compared to other assays 
(34). 
 The observation that there were little to no differences in measures of 
microbial translocation between LSI-None and LSI-Severe animals was 
unexpected. Most studies indicate that increased intestinal disease and loss of T 
cell populations in the gut coincide with increased microbial translocation. 
Additionally, in some human studies and some NHP models this has been 
reported to occur acutely and set the stage for ongoing inflammation throughout 
the course of disease. Our data suggest that while microbial translocation is 
indeed increased during late stage infection, it appears to be independent of the 
severity of intestinal disease. Interestingly, no measurement of microbial 
translocation correlated with CD3 or CD68 staining, or the number of virus-
infected cells in the gut. While these findings are surprising when compared with 
untreated chronic HIV or other models of SIV infection, they agree with some of 
the findings in treated humans where acute cART might preserve T cell 
populations and result in reduced bacterial burden and a positive clinical 
outcome (35, 36). 
 To further elucidate a reason for the apparent lack of microbial 
translocation in this model we examined animals euthanized at 7 and 21 days 
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post infection (acute and asymptomatic) despite their lack of intestinal disease. In 
agreement with majority of the literature on the topic we saw significantly lower 
numbers of CD3 positive T cells in animals 7 days after infection. However, this 
apparent loss of T cells during acute infection did not coincide with any increased 
indicators of intestinal disease via histopathological examination. Further, T cell 
populations at 21 days post infection had recovered to levels similar to those 
seen in uninfected animals in the ileum and colon. The recovery of T cell 
populations after acute infection, in the absence of cART in this model differs 
with conventional thinking on this topic.  
 Looking beyond overt histological indications of intestinal disease we 
sought to evaluate intestinal epithelium integrity directly via the tight junction 
associated protein claudin-3. Tight junction complexes are one of several 
mechanisms that prevent the translocation of microbes across the intestinal 
mucosa. These complexes respond to inflammation in the gut mucosa (37) and 
are directly affected by HIV at least in vitro (38). In spite of a significant losses of 
T cells 7 days post infection we did not see an accompanying loss of epithelial 
claudin-3 during acute or asymptomatic infection; findings that support the lack of 
intestinal disease observed via histological evaluation.  
 We also evaluated the integrity of the epithelial barrier during late stage 
infection where some epithelial degradation was observed in some animals on 
histological evaluation. Interestingly, animals that exhibited severe intestinal 
disease had a significant increase in the % loss of claudin-3 staining in the 
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epithelium compared to PC animals. This loss was not observed in animals 
lacking intestinal disease. 
Theorizing about potential drivers of intestinal disease in this model, we 
sought to quantitate the number of cytotoxic T lymphocytes (CTLs) in the 
intestinal mucosa. CTLs have the potential to increase epithelial apoptosis 
through a maladaptive inflammatory response to HIV or other intracellular 
pathogens and have been implicated in contributing at least in part to epithelial 
damage during acute HIV infection (39). Opposite of our expectations, the 
number of cells containing TIA-1, a protein associated with the pro-apoptotic 
cytoplasmic granules in CTLs, was elevated in LSI-None animals, not LSI-Severe 
animals. While on the surface counterintuitive, this might suggest that 
preservation of CTL populations confers a type of intestinal resilience absent in 
animals who develop intestinal disease. An increase in PD-1 expression on SIV-
specific CTLs in the intestines during chronic infection which coincides with 
functional impairment of adaptive CTL responses has been reported in SIV 
infected rhesus macaques that develop intestinal dysfunction and exhibit 
microbial translocation throughout disease (40). Thus, it is possible that in these 
animals a more robust SIV specific CTL response might, in part, be responsible 
for attenuating both intestinal disease and microbial translocation; and when 
these cells are lost, intestinal dysfunction occurs. 
 A number of potential mechanisms could drive intestinal damage other 
than CD4+ T cell destruction with functional impairment and loss of virus-specific 
CTLs. Dendritic cells, both plasmacytoid (pDCs) and myeloid, are CD68 negative 
46 
and can be infected by HIV. Proliferative pDCs have been reported to infiltrate 
the gut of HIV-infected individuals and up regulate the pro-apoptotic enzyme 
granzyme B (41). Additionally, pro-inflammatory mucosal mDCs can be 
productively infected and are linked to microbial population changes (42). These 
features of inflammation and proliferation in DCs might allow them to contribute 
to observed enteropathy.  
 Shifts in the microbiota of the gut have been reported both in chronically 
infected and cART treated humans and macaques and are associated with 
disease progression. Specific taxa are associated with favorable or unfavorable 
conditions in treated HIV patients. Two examples are increased Proteobacteria 
and proinflammatory tryptophan metabolism (43), and increased Lactobacillales 
and reduced microbial translocation (44). Perhaps the predominant type of 
bacteria that are present and translocating is influencing the gut in unforeseen 
ways.  
Given the rapid progression of disease in this model, it’s possible that 
highly pro-inflammatory microbial translocation only arises with prolonged 
intestinal barrier impairment and not acute episodes of increased inflammation. 
Indeed our experiments indicate that, at least in this model, the first bouts of 
microbial translocation are likely to occur during late stage infection and not in 
acute infection. This is unique in the body of literature regarding microbial 
translocation during HIV and SIV infection. This model has been previously 
shown to recapitulate many aspects of HIV associated inflammation and 
immunological impairment making these findings regarding translocation all the 
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more important. Indeed there are likely other mechanisms involved such as viral 
escape from host control, and further study is warranted.  
Our findings highlight the complexities around chronic inflammation in HIV 
or SIV disease. Collectively these findings support the need for continued study 
of the nature of enteropathy in HIV-infected patients through clinical monitoring 
as well as SIV/macaque modeling. Additionally, we feel there is a discrete need 
for more rigorous approaches and assays to evaluate the presence and amount 
of microbial translocation occurring in the host. Ideally, these data along with 
those from other NHP models of HIV will provide new avenues of therapy and 
allow further improvement of the lives of those affected. 
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Table 1-1. Animal euthanasia dates and treatments. 
 
  
Group Name Abbreviation N Infected Days PI Treatment 
Procedural Control PC 12 No 84-90 
No 
Day 4 4d 8 
Yes 
4 
Day 7 7d 6 7 
Day 10 10d 6 10 
Day 14 14d 6 14 
Day 21 21d 6 21 
Day 42 42d 9 42 
Day 56 56d 9 56 
Late Stage Infected LSI 25 60-101 (Terminal) 
cART cART 5 161-175 cART 
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Table 1-2. Intestinal disease scoring descriptive statistics. 
  
 PC cART LSI 
 Mean Median Pos Mean Median Pos Mean Median Pos 
Giant Cells 0 0 0 0 0 0 4.08 2 58.3 
Mixed 
Infiltrates 
8.58 8.5 100 10.4 11 100 10 10 100 
Epithelium 
Integrity 
0.83 0 16.7 0.4 0 20 1.29 0 45.8 
Villus/Gland 
Abnormality 





Figure 1-1. Intestinal disease scores in uninfected, SIV-infected cART 
treated, and SIV-infected untreated pigtailed macaques. Intestinal disease 
was evaluated in procedural control (PC), SIV-infected animals euthanized at 
days 4, 7, 10, 14, 21, 42, 56 post infection, late stage SIV-infected (LSI) animals, 
and SIV-infected animals on combination antiretroviral therapy (cART). A, B) 
H&E tissue sections of ileum (left) and colon (right) from a LSI animal with no 
intestinal disease. C, D) H&E tissue sections of ileum (left) and colon (right) from 
a LSI animal with severe intestinal disease. E) Representative Balantidium coli 
overgrowth and associated tissue damage in colon of a LSI severe animal. F) 
Representative multinucleated giants cells in the colon of a LSI severe animal. G) 
PC (Blue) and longitudinal intestinal disease scores. H) Comparison of intestinal 
disease scores between PC, cART, and LSI animals. I) Spearman correlation 
between intestinal disease score and plasma viral load (pVL) J) Spearman 
correlation between intestinal disease score and terminal CD4+ T cell count. 
Green and red squares indicate LSI animals with mild or severe intestinal 
disease respectively. Exact p values between groups were calculated by Kruskal-
Wallis test followed by Dunn’s post hoc correction.  
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Figure 1-2. Intestinal disease by tissue site in uninfected, SIV-infected 
cART treated, and SIV-infected, untreated pigtailed macaques. Intestinal 
disease in six intestinal sites were evaluated in procedural control (PC), 
terminally SIV-infected (TI) animals, and SIV-infected animals on combination 
antiretroviral therapy (cART). A) Stomach B) Duodenum C) Jejunum D) Ileum E) 
Cecum F) Colon. Exact p values between groups were calculated by Kruskal-







Figure 1-3. Representative images of caspase-3, CD3, CD68, and SIV 
expression. IHC and ISH in the ileum (left column) and colon (right column) of 
late stage infected (LSI) animals. A, B) Caspase-3 staining of LSI animals 
without intestinal disease. C, D) Caspase-3 staining of LSI animals with severe 
intestinal disease. E, F) CD3 & SIV staining of LSI animals without intestinal 
disease. G, H) CD3 & SIV staining of LSI animals with intestinal disease. I, J) 
CD68 & SIV staining of LSI animals without intestinal disease. K, L) CD68 & SIV 






Figure 1-4. Quantitation of caspase-3, CD3, and CD68 
immunohistochemistry (IHC). Percent region of interest (%ROI) positive by 
IHC in the ileum (left column) and colon (right column) of procedural control (PC) 
and late stage SIV-infected (LSI) animals with and without severe intestinal 
disease. A, B) Caspase-3 staining in PC, and LSI animals with or without 
intestinal disease. C, D) CD3 & SIV staining in PC, and LSI animals with or 
without intestinal disease. E, F) CD68 & SIV staining in PC, and LSI animals with 
or without intestinal disease. Exact p values between groups were calculated by 
Kruskal-Wallis test followed by Dunn’s post hoc correction.  
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Figure 1-5. Quantitation of SIV by in situ hybridization (ISH). The number of 
cells positive by ISH for SIV in the ileum (left column) and colon (right column) of 
late stage SIV-infected (LSI) animals with and without severe intestinal disease. 
A, B) Total cells singly positive for SIV. C, D) Percent of cells double labeled for 
SIV and CD3 or SIV and CD68. Numbers on bar graphs are the average total 
number of cells double-positive for SIV and CD3 or CD68 normalized to one 





Figure 1-6. Relationship between CD3 or CD68 immunohistochemistry (IHC) 
and SIV in gut or plasma. Relationships between markers of interest for all late 
stage SIV-infected (with and without severe intestinal disease) animals were 
examined in the ileum (closed squares) and colon (open circles) A) Relationship 
between CD3 and total number of SIV positive cells. B) Relationship between 
CD68 and total number of SIV positive cells. C) Relationship between CD3 and 
plasma viral load (pVL). D) Relationship between CD68 and pVL. E) Relationship 
between CD3 and caspase-3 F) Relationship between CD68 and caspase-3 G) 
Relationship between caspase-3 and total number of SIV positive cells. H) 
Relationship between caspase-3 and pVL. I) Relationship between total number 
of SIV positive cells and pVL. Spearman’s coefficient and post Bonferroni 
correction exact p values for each analysis are reported where relevant.  
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Figure 1-7. Direct and indirect measures of microbial tranlocation and 
associated inflammation during late stage disease. ELISAs (top row) and 
quantitative PCRs (bottom row) were conducted on samples from procedural 
control (PC), terminally SIV-infected (TI) animals with (red squares) and without 
(black squares) severe intestinal disease, and SIV-infected animals on 
combination antiretroviral therapy (cART). A) Plasma soluble CD163 B) Plasma 
soluble CD14 C) Plasma LPS binding protein D) Plasma 16s ribosomal DNA E) 
Mesenteric lymph node 16s ribosomal DNA F) Liver 16s ribosomal DNA. Open 
symbols represent samples that were below the given assays limit of detection. 
Exact p values between groups were calculated by Kruskal-Wallis test followed 







Figure 1-8. Quantitation of CD3, claudin-3 and TIA-1 immunohistochemistry 
(IHC). Percent region of interest (%ROI) positive for CD3 and percent epithelial 
claudin-3 loss (%Loss) by IHC during acute and asymptomatic infection (top two 
rows). Average number of TIA-1 positive cells per field and percent epithelial 
claudin-3 loss (%Loss) by IHC in late stage SIV-infected (LSI) animals with and 
without severe intestinal disease in the ileum (left column) and colon (right 
column). A, B) CD3 staining in PC, day 7 post infection (acute), and day 21 post 
infection (asymptomatic). C, D) Claudin-3 staining in PC, day 7 post infection 
(acute), and day 21 post infection (asymptomatic). E, F) Claudin-3 staining in PC, 
and LSI animals with or without intestinal disease. G, H) TIA-1 staining in PC, 
and LSI animals with or without intestinal disease. Exact p values between 





Supplemental Table 1-1. Sum of scores for each indicator of intestinal disease 
in late stage infected animals. 
  
All Animals 
 Stomach Duod. Jejunum Ileum Colon Cecum 
Giant Cells 14 34 38 36 46 55 
Mixed Infiltrates 132 177 155 136 137 150 
Epithelium Integrity 8 4 6 25 14 27 
Villus/Gland Abnormality 7 15 23 45 26 9 
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 Stomach Duodenum Jejunum Ileum Colon Cecum 
PC - - - - - - 
cART - - - - - - 
LSI 0.13 0.4 0.67 0.73 1 1.23 
 
Infiltrates 
 Stomach Duodenum Jejunum Ileum Colon Cecum 
PC 0.92 2.00 1.42 1.42 1.33 1.50 
cART 2.20 1.60 1.60 1.40 1.60 2.00 
LSI 1.52 1.92 1.75 1.58 1.58 1.63 
 
Epithelium Integrity 
 Stomach Duodenum Jejunum Ileum Colon Cecum 
PC - - - - - 0.17 
cART - - - - - 0.40 
LSI 0.33 0.08 0.08 0.33 0.25 0.21 
 
Villus/Gland Abnormal 
 Stomach Duodenum Jejunum Ileum Colon Cecum 
PC - - 0.08 - - - 
cART - - - - - - 







Supplemental Table 1-3. Pearson’s correlations between each indicator of 
intestinal disease and overall disease score. 
 
  
Intestinal Disease Category Versus Total Enteropathy 
 r r2 p 
Giant Cells 0.48 0.23 < 0.0001 
Mixed Infiltrates 0.26 0.07 0.01 
Epithelium Integrity 0.41 0.17 < 0.0001 








CHAPTER III.  
Maraviroc with cART Improves Restoration of Memory T Cell Populations 
Over cART Alone in the Blood and Organs of SIV Infected, Suppressed, 
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Combination antiretroviral therapy (cART) fails to correct immunological 
imbalances acquired during acute Human immunodeficiency virus (HIV) 
infection. cART-treated HIV-infected patients exhibit alterations to numbers and 
activation of memory T cells. Using a rapidly progressing SIV/pigtailed macaque 
model of HIV we examined naive, central, and effector memory T cells, and 
expression of CD27, CCR5, CCR7, and HLA-DR in the blood, gut, and draining 
gut and peripheral lymph nodes in uninfected, late stage infected (LSI), animals 
receiving cART, and cART plus Maraviroc (cART+M) using flow cytometry. The 
number of CD4+ T cells was lower in the blood and gut of LSI animals and was 
restored with cART and cART+M in the blood and colon. cART+M animals had 
improved restoration of CD4+ and CD8+ naive and central memory T cells over 
cART alone in the gut. cART+M animals had markedly increased CD27 
expression on naïve, central, and effector CD4+ memory T cells in all body 
regions; and on central, and effector CD8+ memory T cells in the ileum and colon 
indicating earlier differentiation of cells. Finally, reductions were observed to 
CCR7 in the blood and HLA-DR in the gut on CD4+ and CD8+ memory T cells 




 Human immunodeficiency virus (HIV) infection can be effectively 
controlled with modern combination antiretroviral therapy (cART). However, 
cART therapy does not fully reverse some immunological dysfunction acquired 
during acute disease such as CD4+ T cell loss in the jejunum (1, 2). This CD4+ T 
cell dysfunction is associated with impairment of the intestinal mucosa’s ability to 
regulate pro-inflammatory responses to the microbiota (3). Impairment of the 
intestinal immune system is central to theories explaining the chronic 
immunological imbalance in HIV-infected patients receiving cART. Intestinal 
inflammation is triggered by active microbial translocation resulting in 
contamination of the lymphatic fluid and blood with microbial pyrogens. Various 
markers of microbial translocation, principally lipopolysaccharide (LPS) have 
been inversely correlated with immunological restoration and used to predict long 
term clinical improvement (4, 5, 6). Other mechanisms might also provide a path 
to microbial pyrogen dissemination such as dendric cell (mDC) and macrophage 
migration (7, 8). 
 Not only does HIV drive systemic inflammation through destruction of 
CD4+ T cells but also by altering the immunological memory of both CD4+ and 
CD8+ T cells. Naïve (CD28-, CD95+) CD4+ T cells are poorly infected by HIV; 
while central memory T cells (CD28+, CD95+) are the primary cell type infected 
by HIV within the CD4 compartment (9). The latently infected pool of cells largely 
consist of central CD4+ memory T cells and transitional CD4+ memory T cells 
(CD27+) (10, 11). The CD8 compartment isn’t a primary source of viral 
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replication, but chronic inflammation drives hyperactivation and proliferation of 
these cells resulting in more terminally differentiated (CD28+, CD27-) effector 
CD8+ T cells. These terminally differentiated cells are less effective at controlling 
HIV replication and other opportunistic infections due to reduced replicative 
ability and cytotoxicity (12, 13). 
 Therapeutics that suppress viral replication and restore host 
immunological function hold the most potential for patient benefit. The CCR5 
receptor antagonist Maraviroc is an approved cART drug and is effective in 
controlling HIV viral replication. CCR5 receptor antagonists have shown some 
efficacy at preventing cellular senescence in CD8+ T cells and reducing CD4+ 
and CD8+ T cell activation (HLA-DR+) in the blood (14). Some in vitro 
experiments have shown CCR5 antagonists to inhibit the chemotaxis of 
monocytes, macrophages, and dendritic cells; reducing dissemination of 
microbial pryogens systemically (15).  
Due to ethical and technical challenges, data on the effects of Maraviroc 
therapy on organs such as lymph nodes is generally absent from the literature. 
The SIV/macaque model of HIV infection allows examination of aspects of 
disease that might be impractical in humans. These models have been reported 
to recapitulate many aspects of HIV disease including chronic inflammation 
associated with increased microbial translocation (16, 17). We used a rapidly 
progressing SIV/pigtailed macaque model of HIV to examine the effects of cART 
and cART plus Maraviroc (cART+M) on T cell expression of surface markers of 
memory and activation in the blood, intestinal mucosa, draining (colonic & 
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mesenteric) gut (GLN), and peripheral (axillary & inguinal) lymph nodes (PLN). 
This model exhibits a course of disease similar to SIV-infected rhesus macaques 
but in a compressed time span resulting in death around three months post 
inoculation, and can achieve viral suppression on cART therapy (18, 19, 20). The 
aim of the present study was to determine whether Maraviroc in addition to cART 
is more effective than cART alone at restoring the balance of T cell memory 
populations, reduces late stage differentiation of T cell memory populations, and 




Materials and Methods 
Animal studies 
Four cohorts of juvenile pigtailed macaques were used in this study. All 
infected groups were inoculated intravenously with two strains of SIV: the 
immunosuppressive swarm SIV/DeltaB670 and the neurovirulent clone SIV/17E-
Fr, as previously described (18). Late stage infected (LSI) animals were 
euthanized at approximately 84 days post infection (p.i.). Procedural control (PC) 
animals were mock-infected, had blood sampled following the same experimental 
schedule as LSI animals and were euthanized at 84 days p.i. cART animals 
received a regimen containing the nucleotide reverse transcriptase inhibitors 
emtricitabine (FTC, Gilead) and tenofovir (PMPA, Gilead) at doses of 40 and 20 
mg/kg SID SQ respectively, and the integrase inhibitor dolutegravir 
(GlaxoSmithKline) at a dose of 2.5 mg/kg SID SQ, beginning at 12 days after 
virus inoculation. cART+M animals received the same injectable drug regimen as 
cART animals as well as the CCR5 receptor antagonist Maraviroc (Pfizer, New 
York City, NY) at a dose of 20 mg BID PO.  
cART and cART+M animals were monitored for viremia by quantitative 
real-time PCR (qRT-PCR) and experienced marked declines in plasma and CSF 
viral RNA levels, reaching <100 copy equivalents/mL by 50 days after treatment 
initiation. cART and cART+M animals were euthanized between 161-175 days 
post infection.  
 
RNA extraction and viral RNA quantification 
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 Viral RNA from jejunum, ileum, and colon was extracted from 
approximately 50 mg of frozen tissue using the RNeasy kit (Qiagen). Samples 
were eluted in 50 μL of water and analyzed by qRT-PCR for SIV RNA as 
described elsewhere (20). The limit of detection was established at 10 
copies/reaction (100 copy equivalents/mL). 
 
DNA extraction and viral DNA quantification 
DNA from jejunum, ileum, and colon was extracted from approximately 50 
mg of frozen tissue using the DNeasy kit (69504, Qiagen). Samples were eluted 
in 120 μL of water and analyzed by RT-PCR for SIV gag DNA and circular 2-
LTRs as described elsewhere (21). Copy numbers were normalized to the single-
copy cellular gene IFN-. 
 
Intestinal mucosa cell isolation 
Tissue samples from the jejunum, terminal ileum, and distal colon were 
excised and placed in 50 mL conical vials containing cold RPMI 1640 
(ThermoFisher) with 10% FBS (Atlanta Biologicals, Flowery Branch, GA). Each 
sample was trimmed to <1cm, opened longitudinally and washed three times in 
45 mL of cold RPMI supplemented with HEPES (ThermoFisher) buffer. Samples 
were then placed in 7.5 mL of RPMI/HEPES containing 150 u/mL of collagenase 
type II (Worthington, Lakewood, NJ). The mucosa was separated from the 
remaining gut by scraping with a scalpel (Figure 2-1).  
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The mucosa was transferred to a gentleMACS C tube (Miltenyi, Bergisch 
Gladbach, Germany) containing another 7.5 mL of RPMI/HEPES/Collagenase 
(15 mL total). After 1 hour incubation on a rotisserie agitator at 37°C the samples 
were disrupted in a gentleMACS dissociator (Miltenyi) on the “Lung 2” setting. 15 
mL of RPMI/HEPES containing 200 mM dithiothreitol (DTT) was added to the 
samples, which were passed through a 100 μm cell strainer (Corning, Corning, 
NY) and washed with 7.5 mL of RPMI/HEPES/DTT. Samples were then passed 
through a 40 μm cell strainer (Corning), washed with 7.5 mL of 
RPMI/HEPES/DTT and centrifuged for 10 minutes at 800 x g. The resulting 
pellets were washed twice with cold RPMI/HEPES and re-suspended in 10 mL of 
RPMI/HEPES for subsequent counting and staining. 
 
Flow cytometry analysis 
Cells (6 x 106) from gut mucosa were stained with fluorochrome-coupled 
antibodies (Figure 2-2A) for 20 minutes at room temperature (RT) and then fixed 
with 4% paraformaldehyde in PBS for 10 minutes at RT. Whole blood samples 
(100 μL) and cells (106) from lymph nodes were isolated as previously described 
(21) and stained with fluorochrome-coupled antibodies (Figure 2-2A) for 20 
minutes at RT and fixed for 10 minutes with BD FACS Lysing Solution (Becton 
Dickinson, Franklin Lakes, NJ). All antibodies were tested for specificity using 
fluorescence minus one controls. After fixation, samples were analyzed using a 
BD LSR Fortessa cytometer and Diva software version 6.1.3 (Becton Dickinson). 
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FACS data were analyzed using FlowJo version 9.5.1. Representative gating 
schema are presented in Figure 2-2B.  
 
Statistical analyses 
 Comparisons between multiple animal groups were made using Kruskal-
Wallis tests followed by Dunn’s multiple comparison tests between the mean 
ranks of every group. Comparisons between two groups were made using a 
Mann-Whitney test. Microsoft Excel 2013 was used to organize data. GraphPad 
Prism 6.0 was used to perform statistical analyses and generate graphs. Graphs 






Viral RNA and DNA in gut mucosa 
 To evaluate viral replication and the size of the latent viral reservoir in the 
gut of treated animals, copies of SIV RNA per microgram of RNA; and copies of 
SIV DNA and circular 2-LTRs per million cells were quantitated using qRT-PCR 
and RT-PCR respectively. Compared to LSI animals, cART and cART+M groups 
experienced a four log reduction in the mean rank percentage for SIV RNA 
copies in the jejunum (H = 6.694, p = 0.0370), ileum (H = 11.77, p = 0.0003), and 
colon (H = 11.77, p = 0.0003), a two log reduction in the mean rank percentage 
for SIV DNA copies in the jejunum (H = 7.357, p = 0.0147), and colon (H = 9.857, 
p = 0.0007), and a one log reduction in the mean rank percentage for replicative 
circular-2LTRs in the jejunum (H = 9.055, p = 0.0090), and colon (H = 7.261, p = 
0.0184). There was no significant difference in viral RNA, DNA, or circular-2LTRs 
between cART and cART+M groups (Figure 2-3). 
 
CD4+ and CD8+ T cells in the blood, gut mucosa, and lymph nodes. 
 Flow cytometry was conducted to determine the percentage of CD3+ T 
cells expressing CD4 or CD8. The mean rank percentage of CD4+ T cells was 
significantly altered in the blood (H = 7.985, p = 0.0463), jejunum (H = 13.630 p = 
0.0035), ileum (H = 12.940, p = 0.0048), and colon (H = 11.60, p = 0.0089). 
Percent of CD4+ T cells were significantly lower in LSI animals compared to PC 
animals in the jejunum, ileum, and colon. cART animals had significantly higher 
percentages of CD4+ T cells compared to LSI animals in the blood (H = 7.985, p 
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= 0.0290), jejunum (H = 13.63, p = <0.0001), and ileum (H = 12.94, p = 0.0002). 
The mean rank percentage of CD8+ T cells was significantly altered in the blood 
(H = 9.052, p = 0.0286), and jejunum (H = 9.368, p = 0.0248). Percent of CD8+ T 
cells were significantly lower in cART animals compared to LSI animals in the 
blood, and compared to cART+M animals in the jejunum. Dunn’s p values for 
between-group comparisons are shown in Figure 1-4. 
 
T cell memory populations by CD28 and CD95 expression 
 To assess the relative proportions of memory T cells, we examined the 
percentage of CD4+ or CD8+ T cells expressing CD28/CD95+/- (naïve), 
CD28/CD95+/+ (central), or CD28/CD95-/+ (effector). The mean rank percentage 
naïve CD4+ T cells was significantly altered in the jejunum (H = 9.846, p = 
0.0002), ileum (H = 7.269, p = 0.0159), colon (H = 6.000, p = 0.0403), and GLN 
(H = 7.636, p = 0.0038). Percent naïve CD4+ T cells was significantly lower in 
cART animals compared to PC animals in the jejunum, ileum, and colon; and 
compared to cART+M animals in the GLN.  
The mean rank for percentage central memory CD4+ T cells was 
significantly altered in the jejunum (H = 7.565, p = 0.0094), ileum (H = 9.846, p = 
0.0002), and colon (H = 8.769, p = 0.0012). Percent central memory CD4+ T cells 
was significantly lower in cART animals compared to PC animals.  
The mean rank for percentage effector memory CD4+ T cells was 
significantly altered in the jejunum (H = 8.000, p = 0.0048), colon (H = 8.346, p = 
0.0024), and GLN (H = 8.227, p = 0.0016). Percent effector memory CD4+ T was 
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significantly lower in cART+M animals compared to PC animals in the jejunum, 
and colon; and cART animals compared to PC animals in the GLN. No 
differences between cART and cART+M animals were observed. Dunn’s p 
values for between-group comparisons are shown in Figure 2-5A. 
The mean rank for percentage naïve CD8+ T cells was significantly altered 
in the jejunum (H = 9.846, p = 0.0002), ileum (H = 9.846, p = 0.0002), and colon 
(H = 7.731, p = 0.0066). Percent naïve CD8+ T cells was significantly lower in 
cART animals compared to PC animals.  
The mean rank for percentage central memory CD8+ T cells was 
significantly altered in the jejunum (H = 7.385, p = 0.0145), ileum (H = 8.769, p = 
0.0012), and colon (H = 7.731, p = 0.0066). Percent central memory CD8+ T cells 
was significantly higher in cART animals compared to PC animals. No 
differences between cART and cART+M animals were observed. Dunn’s p 
values for between-group comparisons can be found in Figure 2-5B. 
 
T cell memory populations by CD27 expression 
Memory populations were also analyzed by the percentage of CD4+ or 
CD8+ T cells expressing CD27 and the proportion of CD4+ or CD8+ naïve, 
central, or effector cells expressing CD27. The mean rank percentage of CD4+ T 
cells expressing CD27 was significantly altered in the blood (H = 8.326, p = 
0.0012), jejunum (H = 9.846, p = 0.0002), ileum (H = 9.846, p = 0.0002), colon (H 
= 8.115, p = 0.0031), GLN (H = 7.511, p = 0.0059), and PLN (H = 7.848, p = 
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0.0029). Percent of CD4+ T cells expressing CD27 was significantly higher in 
cART+M animals compared to cART animals. 
The mean rank percentage of CD8+ T cells expressing CD27 was 
significantly altered in the ileum (H = 7.423, p = 0.0132), colon (H = 8.769, p = 
0.0012). Percent of CD8+ T cells expressing CD27 was significantly higher in 
cART+M animals compared to PC animals in the ileum and colon; and compared 
to cART animals in the ileum. Dunn’s p values for between-group comparisons 
can be found in Figure 2-6A. 
The median percentage of CD4+ or CD8+ naïve, central, or effector cells 
also expressing CD27 was significantly higher (p < 0.05) on all groups of memory 
T cells in cART+M animals in the gut mucosa compared to cART alone by Mann-
Whitney U test. Excluding naïve CD4+ T cells in the jejunum, all CD8+ T cell 
memory populations in the jejunum, and naïve CD8+ T cells in the ileum and 
colon (Figure 2-6B). 
 
T cell memory activation assessed by CCR5, CCR7, and HLA-DR expression 
To assess markers of T cells activation, the percentage of CD4+ or CD8+ T 
cells expressing CCR5, CCR7, or HLA-DR was measured. No significant 
differences in the mean rank percentages of CD4+ T cells expressing CCR5 were 
observed. The mean rank percentage of CD4+ T cells expressing CCR7 was 
significantly altered in the blood (H = 7.212, p = 0.0090). Percent CD4+ T cells 
expressing CCR7 was significantly lower in cART+M compared to cART animals. 
The mean rank percentage of CD4+ T cells expressing HLA-DR was significantly 
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altered in the jejunum (H = 8.028, p = 0.0042), ileum (H = 7.538, p = 0.0107), and 
colon (H = 6.962, p = 0.0194). Percent of CD4+ T cells expressing HLA-DR was 
significantly lower in cART+M compared to cART animals. Dunn’s p values for 
between-group comparisons are shown in Figure 2-7A. 
The mean rank percentage of CD8+ T cells expressing CCR5 was 
significantly altered in the PLN (H = 6.727, p = 0.0184). Percent CD8+ T cells 
expressing CCR5 was significantly higher in cART+M animals compared to PC 
animals. The mean rank percentage CD8+ T cells expressing CCR7 was 
significantly altered in the blood (H = 7.477, p =0.0062), GLN (H = 7.636, p = 
0.0038), and PLN (H = 6.727 p = 0.0184). Percent CD8+ T cells expressing 
CCR7 was significantly lower in cART+M compared to PC animals. The mean 
rank percentage CD8+ T cells expressing HLA-DR was significantly altered in the 
jejunum (H = 6.615, p = 0.0242), ileum (H = 6.962, p = 0.0192), and colon (H = 
7.565, p = 0.0092). Percent CD8+ T cells expressing HLA-DR was significantly 
lower in cART+M compared to PC animals. Dunn’s p values for between-group 





 Maraviroc has garnered interest as a potential immunomodulatory 
compound in addition to its ability to suppress HIV viral replication (22, 23). In 
this study, the addition of Maraviroc to cART resulted in significant alterations to 
both CD4+ and CD8+ T cell memory populations in the blood, lymph nodes, and 
especially the gut mucosa. Importantly, changes observed in the gut mucosa and 
lymph nodes were not consistently reflected in the blood and no changes in viral 
replication or reservoir size were observed. 
 Early depletion and lack of recovery of CD4+ T cell in the small intestine is 
one of the most cited features of HIV infection (1, 2). Our experiments 
recapitulated these findings in SIV-infected macaques treated with cART and 
cART+M, both of which failed to restore CD4+ T cells to PC levels in the jejunum. 
Interestingly, cART+M also failed to restore CD4+ T cell numbers to those of 
uninfected animals in the ileum, whereas cART alone was sufficient. This might 
be due to the unique nature of illeal peyers patches as dedicated antigen 
induction organs; a process that might be impaired by CCR5 antagonism; as has 
been demonstrated in rats and mice (24, 25).  
 We focused on CD95, CD28, and CD27 to differentiate classes of memory 
T cells, allowing us to infer memory status (naïve, central, and effector) and 
stage of differentiation (early, intermediate, late). Attempts to quantify and purge 
latently infected memory cells have principally focused on naïve, central, and 
transitional memory CD4+ T cells as they are the most productively infected by 
HIV (9, 10, 11). Our data shows an overall increased restoration of central 
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memory CD4+ and CD8+ T cells in the intestine in cART+M as compared with 
cART animals. This was accompanied by a reduction in the number of effector 
memory CD8+ T cells in the intestine. An increase in CD27 expression was 
observed in cART+M vs cART animals on CD4+ T cells in all areas of the body 
examined and on CD8+ T cells in the ileum and colon only. This increase in 
expression was seen on all memory populations (naïve, central, effector) 
excluding naïve CD4+ T cells in the jejunum, all memory CD8+ T cells in the 
jejunum, and naïve CD8+ T cells in the entire gut. These data together suggest 
that Maraviroc with cART is more effective at restoring naïve and central memory 
populations while reducing the amount of terminally differentiated memory T 
cells. Again, these shifts were not accompanied by any observable differences in 
viral replication or reservoir size measured by PCR. Importantly, these shifts 
were most robust in the intestinal mucosa and were not significantly reflected in 
the blood or PLN; sites most commonly sampled in human patients. 
 Restoration of memory T cell populations is a desirable goal in the 
treatment of patients as it should reduce abnormally high inflammation while 
allowing an effective adaptive immune response to pathogens (26, 27). A recent 
publication cites impairment of cART patients’ CD4+ T cells’ ability to up-regulate 
the co-stimulatory molecules CD28 and CD27 (28); phenomena that our data 
suggests could be reversible with Maraviroc. Further, we observed reduction in 
HLA-DR expression on both CD4+ and CD8+ T cells in the gut mucosa of 
cART+M as compared with cART animals. These changes were also not 
reflected in the blood, PLN or GLN. Also supporting the idea of reduced systemic 
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immunological activation and inflammation, cART+M animals had reduced levels 
of CCR7 expression on CD4+ T cells in the blood, and on CD8+ T cells in the 
blood, PLN, and GLN as compared to PC animals. Reduced CCR7 expression 
might indicate less lymph node trafficking occurring in response to antigen 
presentation or inflammatory cytokines by T cells (29, 30).  
 These data support the value of Maraviroc with cART as an 
immunomodulatory compound that might promote restoration of the adaptive 
immune system in patients. Immunological restoration has been attempted in 
patients with Maraviroc intensification with unsatisfactory results in regards to 
CD4+ T cell count and only mild improvement on central memory CD4+ T cell 
populations with observable reductions to activation via HLA-DR (31, 32). 
However, given our findings, these results might be due to patient sampling that 
was limited to the blood; especially given Maraviroc’s propensity to accumulate in 
other tissues such as the gut.  
 Conversely, Maraviroc-induced immune restoration might be undesirable 
in shock and kill approaches to viral eradication. By increasing the naïve and 
central memory T cell pool and reducing its level of terminal differentiation 
Miraviroc might also increase the number of cells that are susceptible to infection 
by HIV (9, 10, 11). Further, infected memory T cell populations with lowered 
activation status might be less effectively targeted by HIV specific CD8+ T cells, 
a mechanism thought to be vital in the clearance of latently infected cells (33). 
Our data, however, did not support this idea as SIV DNA levels remained 
unchanged between cART and cART+M. 
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 What remains unclear is the distribution of HIV infection in these altered 
memory T cell populations with Maraviroc treatment and how HIV specific CD8+ 
T cells might be affected by this therapy. Additionally, it would be interesting to 
determine how therapeutic intensification with Maraviroc compares to initiation of 
cART that includes Maraviroc from the start of antiretroviral therapy. Clinicians 
and researchers should be cautious about extending findings observed in the 
blood to other organs, especially the gut mucosa given our findings. While it 
might confound certain strategies of eradication, clearly Maraviroc holds promise 
as an immune-restorative cART regiment. Further investigation is needed in 




Anti-retroviral drugs for macaques were generously donated by Gilead 
(tenofovir, emtricitabine), GlaxoSmithKline (dolutegravir), and Pfizer (Maraviroc). 
Special thanks to the excellent veterinary and animal care staff at Johns Hopkins 
University School of Medicine. 
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Figure 2-1. Isolation of gut mucosal cells. 
A modified approach to isolating total cells from the lamina propria and 
epithelium of the gut. Mason’s trichrome staining of tissue sections of ileum (top) 
and colon (bottom), showing full thickness gut before removal of musosa (left), 




Panel 1: Jejunum, ileum, colon  Panel 2: Blood, GLN, PLN 
Target Fluor Clone Company  Target Fluor Clone Company 
CCR5 PerCP-Cy5.5 3A9 BD  CCR5 PerCP-Cy5.5 3A9 BD 
CCR7 Pacific Blue TG8 Biolegend  CCR7 Pacific Blue TG8 Biolegend 
CD3 V500 SP34 BD  CD3 FITC SP34 BD 
CD4 BV650 OKT4 Biolegend  CD4 BV650 OKT4 Biolegend 
CD8 BV570 RPA-T8 Biolegend  CD8 BV570 RPA-T8 Biolegend 
CD27 APC M-T271 Biolegend  CD27 APC M-T271 Biolegend 
CD28 Alexa Fluor 700 CD28.2 Biolegend  CD28 Alexa Fluor 700 CD28.2 Biolegend 
CD95 PE DX2 BD  CD95 PE DX2 BD 
HLADR BV605 L234 Biolegend  HLADR APC L234 Biolegend 
Live/Dead Aqua L34965 ThermoFisher      
B 
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Figure 2-2. Flow cytometry analysis of blood, gut mucosa, and lymph 
nodes. 
A modified approach to isolating total cells from the lamina propria and 
epithelium of the gut. A) Antibody panels used to label cells for flow cytometry. B) 
Gating schema used to analyze T cell populations.   
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Figure 2-3. Viral RNA and DNA in the gut. 
SIV RNA (top row), gag DNA (middle row), and circular 2-LTRs (bottom 
row) were measured by RT-PCR in the jejunum (left column), ileum (middle 
column), and colon (right column) of procedural control (PC) animals, animals on 
combination antiretroviral therapy (cART), and animals on combination 
antiretroviral therapy with Maraviroc (cART+M). Open squares represent 
samples that tested below the limit of sensitivity.   
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Figure 2-4. CD4+ and CD8+ T cell population alterations. 
Samples from procedural control (PC) animals, late stage infected (LSI) 
animals, animals on combination antiretroviral therapy (cART), and animals on 
combination antiretroviral therapy that included Maraviroc (cART+M) were 
analyzed using flow cytometry for percentage of CD3+ lymphocytes positive for 
CD4 (top row) or CD8 (bottom row) in the blood, gut, and lymph nodes. Lines 
represent group medians. Exact p values between groups were calculated by 






Figure 2-5. T cell memory population shifts examined by expression of 
CD28 and CD95. 
Samples from procedural control (PC) animals, animals on combination 
antiretroviral therapy (cART), and animals on combination antiretroviral therapy 
that included Maraviroc (cART+M) were analyzed using flow cytometry for 
relative proportions of CD4+ or CD8+ T cells either CD28/CD95+/- (naïve memory), 
CD28/CD95+/+ (central memory), CD28/CD95-/+ (effector memory). A) CD4+ T cell 
naïve memory (top row), central memory (middle row), or effector memory 
(bottom row) in the blood, gut mucosa, and lymph nodes. B) CD8+ T cell naïve 
memory (top row), central memory (middle row), or effector memory (bottom row) 
in the blood, gut and lymph nodes. Lines represent group medians. Exact p 
values between groups were calculated by Kruskal-Wallis test followed by 







Figure 2-6. Distribution of CD27 expression on T cell memory subsets. 
Samples from procedural control (PC) animals, animals on combination 
antiretroviral therapy (cART), and animals on combination antiretroviral therapy 
that included Maraviroc (cART+M) were analyzed using flow cytometry for 
relative proportions of CD4+ or CD8+ T cells positive for CD27. A) Percent of 
CD4+ (top row) or CD8+ (bottom row) T cells expressing CD27 in the blood, gut 
mucosa, and lymph nodes. Lines represent group medians. Exact p values 
between groups were calculated by Kruskal-Wallis test followed by Dunn’s post 
hoc correction. B) Percent of CD4+ (top row) or CD8+ (bottom row) T cell memory 
populations (naïve, central, or effector) expressing CD27 in the blood, gut 
mucosa, and lymph nodes of animals on cART or cART & Maraviroc. Asterisks 
indicate mean ranks that were significantly different between indicated groups 






Figure 2-7. T cell activation evaluated by expression of CCR5, CCR7, and 
HLA-DR. 
Samples from procedural control (PC) animals, animals on combination 
antiretroviral therapy (cART), and animals on combination antiretroviral therapy 
that included Maraviroc (cART+M) were analyzed using flow cytometry for 
relative proportions of CD4+ or CD8+ T cells positive for CCR5, CCR7, and HLA-
DR. A) Percent of CD4+ T cells expressing CCR5 (top row), CCR7 (middle row), 
or HLA-DR (bottom row) in the blood, gut mucosa, and lymph nodes. B) Percent 
of CD8+ T cells expressing CCR5 (top row), CCR7 (middle row), or HLA-DR 
(bottom row) in the blood, gut mucosa, and lymph nodes. Lines represent group 
medians. Exact p values between groups were calculated by Kruskal-Wallis test 

















CHAPTER IV.  
Summary and Concluding Remarks 
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 The findings presented in this dissertation are of key interest to 
researchers interested in HIV associated enteropathy and its relationship with the 
mucosal immune system, systemic inflammation, and microbial translocation. We 
examined a unique accelerated SIV model of HIV infection; thoroughly evaluating 
histopathological evidence of intestinal disease and found that, at least in this 
model, severe intestinal disease is not evident until late stage infection. This 
intestinal disease was highly associated with the number of CD3+ T cells in the 
mucosa of the ileum and colon. Additionally, these reductions in T cell staining 
were correlated with the amount of virally infected cells in the ileum and colon, 
plasma viral load, and apoptosis. The most significant findings from Chapter II 
were that while CD3+ T cells were indeed depleted during acute infection, as is 
often reported in HIV/SIV infection, there was no associated disruption of the 
epithelial barrier. Further, in animals with severe intestinal disease during chronic 
infection while there was disruption to the epithelial barrier, this did not correlate 
with increased microbial translocation as indicated by six different experiments 
measuring markers of translocation. We went on to demonstrate that cytotoxic T 
lymphocytes might play some role in preventing the development of intestinal 
disease. 
As discussed in the Introduction, while intestinal disease and microbial 
translocation are often linked during HIV/SIV infection, the story is incomplete. 
The overall conclusion from this work is that microbial translocation does indeed 
occur during HIV/SIV infection, particularly during chronic, untreated infection. 
However, limitations of current methodologies for measuring microbial 
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translocation should be kept in mind and used to cautiously frame findings 
regarding microbial translocation; the findings in one experimental system or 
cohort of humans might have limited implications. Future studies regarding 
microbial translocation should incorporate our expanded understanding of the 
intestinal barrier and recent developments regarding the microbiota to refine the 
model for HIV/SIV associated inflammation. The intestinal barrier is maintained 
by a mucus layer, excreted antimicrobial peptides and IgA, epithelial tight 
junctions, and the mucosal immune system (1-3). Examination of one aspect of 
the intestinal barrier such as epithelial tight junctions might not be adequate to 
draw broad implications about the level of microbial translocation. Further, 
antigen induction can occur in the absence of intestinal barrier breakdown 
through the activities of dendritic cells and M-cells lining the luminal surface of 
the lamina propria.  
Other potential sources of systemic inflammation might lie not in the 
induction or translocation of microbes and their antigens but in alterations to the 
microbiota species in the gut. A recent series of studies have linked specific 
bacteria taxa with alterations to tryptophan metabolism towards the pro-
inflammatory kynurenine pathway (4); an inflammatory pathway that has been 
associated with inflammation in HIV (5, 6) and in the accelerated SIV macaque 
model of HIV disease (7). Additionally, some research has indicated that the 
presence of specific microbial taxa might increase recovery of CD4+ T cells and 
attenuate microbial translocation in the absence of cART, one example being 
increased proportions of Lactobacillales (8).  
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Expanding on the observation that intestinal disease in this model is highly 
associated with the number of CD3+ T cells and is prevented by cART; we 
sought to examine specific changes to T cell memory, differentiation status, and 
activation. One aspect of HIV/SIV cART that needs clarification is to what extent 
suppression of viral replication equates to immunological reconstitution. There is 
some evidence that initiation of cART during acute SIV infection in rhesus 
macaques might have a beneficial effect on correcting some immunological 
imbalances due to HIV infection (9). However, our findings indicated the 
opposite: initiation of cART at twelve days post infection was not sufficient to 
restore CD4+ and CD8+ T cell memory in the gut mucosa to proportions seen in 
uninfected animals; specifically with regards to numbers of naïve and central 
memory cells. Additionally, expression of CD27, a T cell co-stimulatory receptor 
that is lost on cells once they become exhausted in late stage differentiation, was 
lower on CD4+ T cells in every tissue examined, and on CD8+ T cells in the 
ileum and colon for animals receiving cART therapy. Together this indicates that 
the proportions of memory T cells are shifted and might be less able to 
appropriately and adaptively respond to antigen.  
We next compared cART with cART including the CCR5 receptor 
antagonist Maraviroc. Maraviroc has garnered some attention in HIV therapeutics 
as a potential immunological modulatory agent as it interferes with accelerated 
chemotaxis of immunological cells towards sites of inflammation (10-12). We saw 
that cART+M was effective in restoring the proportions of CD4+ and CD8+ 
memory T cells towards those seen in uninfected animals over cART alone in the 
100 
intestinal mucosa. Most remarkably, expression of CD27 was markedly 
increased in all regions of the body examined compared to cART for CD4+ T 
cells and in the ileum and colon for CD8+ T cells. This increase in CD27 
expression was seen on all types of CD4+ T cell memory (naïve, central, and 
effector) in the intestinal mucosa and on central and effector CD8+ memory T 
cells. This agrees with theories that Maraviroc holds therapeutic immunological 
benefit in the context of SIV disease. Restoration of the proportions of mucosal 
memory T cells in combination with a reduction in their exhaustion indicates the 
adaptive immune system is more able to respond appropriately and effectively in 
cART+M animals. This observation is further supported by our findings that 
markers of T cell activation were significantly lower in cART+M animals: CCR7 in 
the blood and lymph nodes (for CD8s) and HLA-DR in the gut mucosa for both 
CD4+ and CD8+ T cells. 
Therapies that can effectively suppress viral replication and restore host 
immunity stand to greatly improve the quality of life of patients. A better 
understanding of how HIV/SIV can impact the intestinal immune system and 
possibly influence microbial translocation might offer novel therapeutic 
approaches that can be used in combination with cART and Maraviroc. Thus, 
important features of HIV and SIV infection that need clarification are the true 
quantity of microbial translocation occurring during infection and the amount of 
inflammation associated with changes in the microbiota that are independent of 
microbial translocation. This can be achieved with a combination of new 
technologies that allow researchers to more carefully examine microbially 
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sourced inflammation and thoughtful experimentation that keeps the complex 
physiology of the gut in mind. A revised model for systemic inflammation during 
HIV infection might allow clinicians to develop therapies that effectively silence 
most ailments experienced by HIV-infected individuals. Developing such a 
therapy in combination with highly effective antiretroviral agents stands to greatly 
benefit HIV-infected individuals by reducing inflammation and the incidence of 
non-AIDS related chronic illnesses. This and other strategies to reduce the 
incidence of chronic diseases experienced by HIV-infected individuals might one 
day eliminate the need for viral eradication from the host; a goal that has been 
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